EP3119432B1 - Antibodies against immunogenic glycopeptides, composition comprising the same and use thereof - Google Patents
Antibodies against immunogenic glycopeptides, composition comprising the same and use thereof Download PDFInfo
- Publication number
- EP3119432B1 EP3119432B1 EP15765633.1A EP15765633A EP3119432B1 EP 3119432 B1 EP3119432 B1 EP 3119432B1 EP 15765633 A EP15765633 A EP 15765633A EP 3119432 B1 EP3119432 B1 EP 3119432B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- variable region
- amino acid
- chain variable
- antibody
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title description 16
- 230000002163 immunogen Effects 0.000 title description 9
- 102000002068 Glycopeptides Human genes 0.000 title description 6
- 108010015899 Glycopeptides Proteins 0.000 title description 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 91
- 239000000427 antigen Substances 0.000 claims description 82
- 102000036639 antigens Human genes 0.000 claims description 81
- 108091007433 antigens Proteins 0.000 claims description 81
- 206010028980 Neoplasm Diseases 0.000 claims description 47
- 201000011510 cancer Diseases 0.000 claims description 33
- 125000000539 amino acid group Chemical group 0.000 claims description 28
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims description 23
- 150000001720 carbohydrates Chemical class 0.000 claims description 18
- 238000011282 treatment Methods 0.000 claims description 17
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 14
- 206010033128 Ovarian cancer Diseases 0.000 claims description 13
- 206010006187 Breast cancer Diseases 0.000 claims description 11
- 208000026310 Breast neoplasm Diseases 0.000 claims description 11
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 8
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 8
- 201000002528 pancreatic cancer Diseases 0.000 claims description 8
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 8
- 230000005012 migration Effects 0.000 claims description 7
- 238000013508 migration Methods 0.000 claims description 7
- 206010060862 Prostate cancer Diseases 0.000 claims description 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 238000002512 chemotherapy Methods 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 239000004037 angiogenesis inhibitor Substances 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 230000005855 radiation Effects 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 92
- 102100030335 Midkine Human genes 0.000 description 73
- 241000282414 Homo sapiens Species 0.000 description 40
- 229940027941 immunoglobulin g Drugs 0.000 description 15
- 235000014633 carbohydrates Nutrition 0.000 description 14
- 239000012634 fragment Substances 0.000 description 14
- 108090000765 processed proteins & peptides Proteins 0.000 description 14
- 108060003951 Immunoglobulin Proteins 0.000 description 13
- 239000011324 bead Substances 0.000 description 13
- 102000018358 immunoglobulin Human genes 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 12
- 235000001014 amino acid Nutrition 0.000 description 12
- 238000003556 assay Methods 0.000 description 12
- 102000004196 processed proteins & peptides Human genes 0.000 description 12
- 229940024606 amino acid Drugs 0.000 description 10
- 150000001413 amino acids Chemical class 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 238000007920 subcutaneous administration Methods 0.000 description 9
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 8
- 230000001419 dependent effect Effects 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 210000004408 hybridoma Anatomy 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 241000283984 Rodentia Species 0.000 description 6
- 238000010494 dissociation reaction Methods 0.000 description 6
- 230000005593 dissociations Effects 0.000 description 6
- 230000005847 immunogenicity Effects 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 229960005486 vaccine Drugs 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 238000007912 intraperitoneal administration Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 230000004614 tumor growth Effects 0.000 description 5
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 4
- 108010078791 Carrier Proteins Proteins 0.000 description 4
- 102000014914 Carrier Proteins Human genes 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 4
- 239000004473 Threonine Substances 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 210000004988 splenocyte Anatomy 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 231100000023 Cell-mediated cytotoxicity Toxicity 0.000 description 3
- 206010057250 Cell-mediated cytotoxicity Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- 102000015728 Mucins Human genes 0.000 description 3
- 108010063954 Mucins Proteins 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 239000012979 RPMI medium Substances 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 230000007910 cell fusion Effects 0.000 description 3
- 230000005890 cell-mediated cytotoxicity Effects 0.000 description 3
- 230000021615 conjugation Effects 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 231100000276 dose-dependent cytotoxicity Toxicity 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 230000008676 import Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 229960000310 isoleucine Drugs 0.000 description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 230000012846 protein folding Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000004088 simulation Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 239000004474 valine Substances 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 2
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 2
- 108010087819 Fc receptors Proteins 0.000 description 2
- 102000009109 Fc receptors Human genes 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 238000002841 anti-cancer assay Methods 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229940009098 aspartate Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000012933 kinetic analysis Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 229960000814 tetanus toxoid Drugs 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- YMXHPSHLTSZXKH-RVBZMBCESA-N (2,5-dioxopyrrolidin-1-yl) 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoate Chemical compound C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)ON1C(=O)CCC1=O YMXHPSHLTSZXKH-RVBZMBCESA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 108010060123 Conjugate Vaccines Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- GHAZCVNUKKZTLG-UHFFFAOYSA-N N-ethyl-succinimide Natural products CCN1C(=O)CCC1=O GHAZCVNUKKZTLG-UHFFFAOYSA-N 0.000 description 1
- HDFGOPSGAURCEO-UHFFFAOYSA-N N-ethylmaleimide Chemical compound CCN1C(=O)C=CC1=O HDFGOPSGAURCEO-UHFFFAOYSA-N 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229920002535 Polyethylene Glycol 1500 Polymers 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 102100035328 Transmembrane protein 258 Human genes 0.000 description 1
- 241000021375 Xenogenes Species 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000009824 affinity maturation Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940124650 anti-cancer therapies Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 238000011398 antitumor immunotherapy Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000012575 bio-layer interferometry Methods 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Natural products N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 201000000464 cone-rod dystrophy 2 Diseases 0.000 description 1
- 229940031670 conjugate vaccine Drugs 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000009133 cooperative interaction Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 229940031348 multivalent vaccine Drugs 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 108010087904 neutravidin Proteins 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000004526 pharmaceutical effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000012557 regeneration buffer Substances 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000012536 storage buffer Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- VUYXVWGKCKTUMF-UHFFFAOYSA-N tetratriacontaethylene glycol monomethyl ether Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO VUYXVWGKCKTUMF-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001296 transplacental effect Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/001173—Globo-H
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6012—Haptens, e.g. di- or trinitrophenyl (DNP, TNP)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Definitions
- the present invention relates to the field of immunotherapy of cancer. More particularly, the disclosed invention relates to an antibody against an immunogenic glycopeptide, a pharmaceutical composition comp comprising the antibody and to the antibody for use cancer therapy.
- Globo H is a hexasaccharide and belongs to a large number of tumor-associated carbohydrate antigens that are overexpressed on the surface of various epithelial cancer cells, including breast, colon, ovarian, pancreatic, lung, and prostate cancer cells.
- the aberrant expression of Globo H renders it an attractive candidate for immunotherapy and the development of cancer vaccines for Globo H-positive cancers.
- Globo H is often tolerated by the immune system, and consequently, the immunogenicity induced by Globo H is limited. Further, the production of antibody against a specific immunogen typically involves the cooperative interaction of two types of lymphocytes, B-cells and helper T-cells. Yet, Globo H alone cannot activate helper T-cells, which also attributes to the poor immunogenicity of Globo H. Accordingly, the immunization with Globo H is often typified by low titer of immunoglobulin M (IgM) and failure to class switch to immunoglobulin G (IgG), as well as ineffective antibody affinity maturation.
- IgM immunoglobulin M
- IgG immunoglobulin G
- T-epitopes such as keyhole limpet hemocyanin (KLH) or detoxified tetanus toxoid (TT)
- KLH keyhole limpet hemocyanin
- TT detoxified tetanus toxoid
- US 20010048929 provided a multivalent immunogenic molecule, comprising a carrier molecule containing at least one functional T-cell epitope, and multiple different carbohydrate fragments each linked to the carrier molecule and each containing at least one functional B-cell epitope, wherein said carrier molecule imparts enhanced immunogenicity to said multiple carbohydrate fragments and wherein the carbohydrate fragment is Globo H, LeY or STn.
- US 20120328646 provides a carbohydrate based vaccine containing Globo H (B cell epitope) chemically conjugated to the immunogenic carrier diphtheria toxin cross-reacting material 197 (DT-CRM 197) (Th epitope) via a p-nitrophenyl linker, which provides immunogenicity in breast cancer models, showing delayed tumorigenesis in xenograft studies.
- US 20120263749 relates to a polyvalent vaccine for treating cancer comprising at least two conjugated antigens selected from a group containing glycolipid antigen such as Globo H, a Lewis antigen and a ganglioside, polysaccharide antigen, mucin antigen, glycosylated mucin antigen and an appropriate adjuvant.
- conjugation of carbohydrates to a carrier protein poses several new problems.
- the foreign carrier protein and the linker for attaching the carrier protein and the carbohydrate may elicit strong B-cell responses, thereby leading to the suppression of an antibody response against the carbohydrate epitope ( Ingale S. et al. Robust immune responses elicited by a fully synthetic three-component vaccine. Nat Chem Biol. 2007 Oct;3(10):663-7 . Epub 2007 Sep 2).
- Ingale et al. also indicated that the conjugation chemistry is difficult to control, resulting in conjugates with ambiguities in composition and structure, which may affect the reproducibility of an immune response.
- Slovin et al. taught that the same vaccine gave low median IgG and IgM antibody titers in a clinical trial of relapsed prostate cancer patients ( Slovin SF, et al. Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with alpha-N-acetylgalactosamine-O-serine/threonine conjugate vaccine. J Clin Oncol. 2003;21:4292-4298 ).
- the present disclosure is directed to an antibody which specifically binds to Globo H according to any of the above-mentioned aspects of the present disclosure.
- the antibody is a monoclonal antibody.
- the antibody is a chimeric or humanized antibody.
- the present disclosure is directed to a pharmaceutical composition for treating a cancer in a subject in need thereof.
- the pharmaceutical composition comprises (1) a therapeutically effective amount of the antibody according to any of the above-mentioned aspects of the present disclosure, and optionally (2) a pharmaceutically acceptable carrier.
- the present disclosure is directed to a method of treating a cancer in a subject in need thereof.
- the method includes administering to the subject the pharmaceutical composition the antibody or pharmaceutical composition according to any of the above-mentioned aspects of the present disclosure.
- the present invention is based, at least, on the finding that recombinant antibodies specifically bind to Globo H for treating cancer expression tumor-associated carbohydrate antigens.
- antigen as used herein is defined as a substance capable of eliciting an immune response. Said immune response may involve either antibody production, or the activation of specific immunologically-competent cells, or both.
- immunogen refers to an antigen capable of inducing the production of an antibody.
- immunoogenicity generally refers to the ability of an immunogen or antigen to stimulate an immune response.
- epitope refers to a unit of structure conventionally bound by an immunoglobulin VH/VL pair.
- An epitope defines the minimum binding site for an antibody, and thus represent the target of specificity of an antibody.
- antibody refers to a whole antibody molecule or a fragment, variant or derivative thereof, which is capable of recognizing or binding to an antigen.
- Most natural antibodies have two heavy chains and two light chains linked to each other by disulfide bonds.
- the light chain includes a variable domain (VL) and a constant domain (CL); while the heavy chain includes a variable domain (VH) and three constant domains (CHI, CH2 and CH3, collectively referred to as CH).
- VL variable domain
- VH constant domain
- CH constant domains
- VH and VL regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDR), interspersed with regions that are more conserved, termed framework regions (FR).
- CDR complementarity determining regions
- FR framework regions
- Each VH and VL is, composed of three CDRs and four FRs arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.
- the constant region domains of the light (CL) and heavy (CH) chains confer important biological properties such as antibody chain association, secretion, trans-placental mobility, complement binding, and binding to Fc receptors (FcR).
- antibody variable domain refers to the portions of the light and heavy chains of antibody molecules that include amino acid sequences of Complementarity Determining Regions (CDRs; i.e., CDR1, CDR2, and CDR3), and Framework Regions (FRs).
- CDRs Complementarity Determining Regions
- FRs Framework Regions
- amino acid positions assigned to CDRs and FRs can be defined according to Kabat (Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, Md., 1987 and 1991 )). Amino acid numbering of antibodies or antigen binding fragments is also according to that of Kabat.
- CDRs Complementarity Determining Regions
- CDR1, CDR2, and CDR3 refers to the amino acid residues of an antibody variable domain the presence of which are necessary for antigen binding.
- Each variable domain typically has three CDR regions identified as CDR1, CDR2 and CDR3.
- H-CDR refers to the CDR of the heavy chain and L-CDR refers to the CDR of the light chain.
- the term "monoclonal antibody” refers to an antibody molecule obtained from a single type of antibody-producing cells.
- chimeric antibody refers to an antibody comprising a variable region from one source or species and at least a portion of a constant region derived from a different source or species, usually prepared by recombinant DNA techniques. It is preferred that the CDRs of a chimeric antibody have one origin, while the remainder of the antibody has a different origin.
- the chimeric antibody may be a humanized antibody in which the antigen binding sequences/variable domains of a non-human antibody have been grafted onto human antibody framework regions.
- humanized antibody refers to forms of antibodies that contain sequences from non-human (e.g., murine) antibodies as well as human antibodies. Such antibodies contain minimal sequence derived from non-human immunoglobulin.
- the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the hypervariable loops correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin sequence.
- the humanized antibody optionally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin.
- Fc immunoglobulin constant region
- the humanized forms of rodent antibodies will essentially comprise the same CDR sequences of the parental rodent antibodies, although certain amino acid substitutions may be included to increase affinity, increase stability of the humanized antibody, or for other reasons.
- CDR loop exchanges do not uniformly result in an antibody with the same binding properties as the antibody of origin, changes in framework residues (FR), residues involved in CDR loop support, might also be introduced in humanized antibodies to preserve antigen binding affinity.
- FR framework residues
- the left-hand direction is the amino-terminal (N-terminal) direction and the right-hand direction is the carboxy-terminal (C-terminal) direction, in accordance with standard usage and convention.
- Percentage (%) amino acid sequence identity with respect to the amino acid sequences identified herein is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the specific polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percentage sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared.
- sequence comparison between two amino acid sequences was carried out by computer program Blastp (protein-protein BLAST) provided online by National Center for Biotechnology Information (NCBI).
- NCBI National Center for Biotechnology Information
- the percentage amino acid sequence identity of a given amino acid sequence A to a given amino acid sequence B is calculated by the formula as follows: X Y ⁇ 100 ⁇ % where X is the number of amino acid residues scored as identical matches by the sequence alignment program BLAST in that program's alignment of A and B, and where Y is the total number of amino acid residues in A or B, whichever is shorter.
- amino acid sequences of proteins/polypeptides are contemplated as being encompassed by the present disclosure, providing that the variations in the amino acid sequence maintain at least 80% such as at least, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% and 99%.
- conservative amino acid replacements are contemplated. Conservative replacements are those that take place within a family of amino acids that are related in their side chains.
- Genetically encoded amino acids are generally divided into families: (1) acidic aspartate, glutamate; (2) basic lysine, arginine, histidine; (3) nonpolar alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan; and (4) uncharged polar glycine, asparagine, glutamine, cysteine, serine, threonine, tyrosine.
- More preferred families are: serine and threonine are aliphatic-hydroxy family; asparagine and glutamine are an amide-containing family; alanine, valine, leucine and isoleucine are an aliphatic family; and phenylalanine, tryptophan, and tyrosine are an aromatic family.
- serine and threonine are aliphatic-hydroxy family
- asparagine and glutamine are an amide-containing family
- alanine, valine, leucine and isoleucine are an aliphatic family
- phenylalanine, tryptophan, and tyrosine are an aromatic family.
- Whether an amino acid change results in a functional peptide can readily be determined by assaying the specific activity of the polypeptide derivative. Fragments or analogs of proteins/polypeptides can be readily prepared by those of ordinary skill in the art. Preferred amino- and carboxy-termini of fragments or analogs occur near boundaries of functional domains.
- antibody mutant refers to an amino acid sequence variant of the species-dependent antibody wherein one or more of the amino acid residues of the species-dependent antibody have been modified. Such mutants necessarily have less than 100% sequence identity or similarity with the species-dependent antibody.
- the antibody mutant will have an amino acid sequence having at least 75% amino acid sequence identity or similarity with the amino acid sequence of either the heavy or light chain variable domain of the species-dependent antibody, more preferably at least 80%, more preferably at least 85%, more preferably at least 90%, and most preferably at least 95%.
- Identity or similarity with respect to this sequence is defined herein as the percentage of amino acid residues in the candidate sequence that are identical (i.e., same residue) or similar (i.e., amino acid residue from the same group based on common side-chain properties, see below) with the species-dependent antibody residues, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity. None of N-terminal, C-terminal, or internal extensions, deletions, or insertions into the antibody sequence outside of the variable domain shall be construed as affecting sequence identity or similarity.
- antigen-binding portion of an antibody (or simply “antigen portion”), refers to full length or one or more fragments of an antibody that retain the ability to specifically bind to an antigen. It has been shown that the antigen-binding function of an antibody can be performed by fragments of a full-length antibody.
- binding fragments encompassed within the term "antigen-binding portion" of an antibody include a Fab fragment, a monovalent fragment consisting of the V L , V H , C L and CH1 domains; a F(ab) 2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; a Fd fragment consisting of the V H and CH1 domains; a Fv fragment consisting of the V L and V H domains of a single arm of an antibody; a dAb fragment ( Ward et al., 1989 Nature 341:544-546 ), which consists of a V H domain; and an isolated complementarity determining region (CDR), or any fusion proteins comprising such antigen-binding portion.
- a Fab fragment a monovalent fragment consisting of the V L , V H , C L and CH1 domains
- F(ab) 2 fragment a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at
- treatment are used herein broadly to include a preventative (e.g., prophylactic), curative, or palliative measure that results in a desired pharmaceutical and/or physiological effect.
- a preventative e.g., prophylactic
- curative e.g., or palliative measure that results in a desired pharmaceutical and/or physiological effect.
- the effect is therapeutic in terms of partially or completely curing or preventing cancer.
- treatment refers to application or administration of the present immunogenic glycopeptide, antibody, or pharmaceutical composition comprising any of the above to a subject, who has cancer, a symptom of cancer, a disease or disorder secondary to cancer, or a predisposition toward cancer, with the purpose to partially or completely alleviate, ameliorate, relieve, delay onset of, inhibit progression of, reduce severity of, and/or reduce incidence of one or more symptoms or features of cancer.
- a “treatment” includes not just the improvement of symptoms or decrease of markers of the disease, but also a cessation or slowing of progress or worsening of a symptom that would be expected in absence of treatment.
- the term “treating” can also be used herein in a narrower sense which refers only to curative or palliative measures intended to ameliorate and/or cure an already present disease state or condition in a patient or subject.
- preventing refers to a preventative or prophylactic measure that stops a disease state or condition from occurring in a patient or subject. Prevention can also include reducing the likelihood of a disease state or condition from occurring in a patient or subject and impeding or arresting the onset of said disease state or condition.
- effective amount refers to the quantity of a component which is sufficient to yield a desired response. Effective amount may be expressed, for example, in grams, milligrams or micrograms or as milligrams per kilogram of body weight (mg/kg). The term also refers to an amount of a pharmaceutical composition containing an active component or combination of components. The specific effective or sufficient amount will vary with such factors as the particular condition being treated, the physical condition of the patient (e.g., the patient's body mass, age, or gender), the type of mammal or animal being treated, the duration of the treatment, the nature of concurrent therapy (if any), and the specific formulations employed and the structure of the compounds or its derivatives.
- therapeutically effective amount refers to the quantity of an active component which is sufficient to yield a desired therapeutic response.
- a therapeutically effective amount is also one in which any toxic or detrimental effects of the compound or composition are outweighed by the therapeutically beneficial effects.
- a "pharmaceutically acceptable carrier” is one that is suitable for use with the subjects without undue adverse side effects (such as toxicity, irritation, and allergic response) commensurate with a reasonable benefit/risk ratio.
- each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the pharmaceutical composition.
- the carrier can be in the form of a solid, semi-solid, or liquid diluent, cream or a capsule.
- the carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation, and is selected to minimize any degradation of the active agent and to minimize any adverse side effects in the subject.
- subject refers to a mammal including the human species that is treatable with antibody.
- subject is intended to refer to both the male and female gender unless one gender is specifically indicated.
- novel recombinant anti-Globo H antibodies and anti-Globo H-binding peptides specifically binding to Globo H or its derivatives and methods of their use in anti-tumor immunotherapies, such as the treatment of cancer.
- antibodies Once bound to a cancer antigen, antibodies can induce antibody-dependent cell-mediated cytotoxicity, activate the complement system, and prevent a receptor interacting with its ligand (such as Globo H).
- the compositions comprising the anti-Globo H-binding peptides or anti-Globo H antibodies described herein are useful in anti-cancer therapies.
- compositions comprising the anti-Globo H-binding peptides or anti-Globo H antibodies can combine with an additional anti-tumor agent.
- the present embodiments provide the complementarity determining region (CDR) sequences of specific anti-Globo H antibodies, which can be used in a variety of anti-Globo H-binding peptides.
- the present invention provides a humanized or chimeric antibody or an antigen-binding fragment thereof capable of binding to Globo H or its derivatives.
- the present disclosure provides an isolated anti-Globo H antibody or an antigen-binding portion thereof, comprising at least one of a heavy chain complementarity determining region 1 (H-CDR1) consisting of the amino acid residues of GFSLSTFDMGVG (SEQ ID NO: 1), GSSLSTFDVGVG (SEQ ID NO: 2), GFSLGTFDLGIG (SEQ ID NO: 3), GFSLSTFDLGIG (SEQ ID NO: 4) or a variant having amino acid sequence with at least 80% identity to any of SEQ ID NOs: 1 to 4; a heavy chain CDR2 (H-CDR2) consisting of the amino acid residues of HIWWDDDKYYNPA (SEQ ID NO:5), HIWGDDDKYYNPA (SEQ ID NO: 6) or a variant having amino acid sequence with at least 80% identity to any of SEQ ID NOs: 5 and 6; and a heavy chain CDR3 (H-CDR3) consisting of the amino acid residues of GFSLST
- sequence identity as mentioned above is at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%.
- the present disclosure provides an isolated anti-Globo H antibody or an antigen-binding portion thereof, comprising (i) a heavy chain variable region comprising a heavy chain variable region comprising H-CDR1 selected from the group consisting of SEQ ID NOs: 1 to 4, H-CDR2 selected from the group consisting of SEQ ID NOs: 5 and 6 and H-CDR3 selected from the group consisting of SEQ ID NOs: 7 to 9, and (ii) light chain variable regions comprising L-CDR1 selected from the group consisting of SEQ ID NOs: 10 to 13, L-CDR2 selected from the group consisting of SEQ ID NOs: 14 to 16 and L-CDR3 selected from the group consisting of SEQ ID NOs: 17 to 19.
- H-CDR1 is SEQ ID NO:3; H-CRD2 is SEQ ID NO:5; H-CDR3 is SEQ ID NO:8; L-CDR1 is SEQ ID NO:10; L-CDR2 is SEQ ID NO:16; and L-CDR3 is SEQ ID NO:18.
- H-CDR1 has the amino acid sequence of SEQ ID NO:3 or SEQ ID NO:4; H-CDR2 has the amino acid sequence of SEQ ID NO:5; H-CDR3 has the amino acid sequence of SEQ ID NO: 8; L-CDR1 has the amino acid sequence of SEQ ID NO:12; L-CDR2 has the amino acid sequence of SEQ ID NO:16 and L-CDR3 has the amino acid sequence of SEQ ID NO:18.
- the present disclosure provides a heavy chain variable region comprising a heavy chain variable region comprising H-CDR1 selected from the group consisting of SEQ ID NOs: 1 to 4, H-CDR2 selected from the group consisting of SEQ ID NOs: 5 and 6 and H-CDR3 selected from the group consisting of SEQ ID NOs: 7 to 9.
- the heavy chain variable region can comprise SEQ ID NO: 3 as H-CDR1, SEQ ID NO: 5 H-CDR2 and SEQ ID NO: 8 as H-CDR3.
- the present disclosure provides a light chain variable region comprising L-CDR1 selected from the group consisting of SEQ ID NOs: 10 to 13, L-CDR2 selected from the group consisting of SEQ ID NOs: 14 to 16 and L-CDR3 selected from the group consisting of SEQ ID NOs: 17 to 19.
- the light chain variable region comprising SEQ ID NO: 12 as L-CDR1, SEQ ID NO: 16 as L-CDR2 and SEQ ID NO: 18 as L-CDR3.
- the isolated anti-Globo H antibody is a monocloncal antibody.
- Monoclonal antibodies to Globo H can be made according to knowledge and skill in the art. For example, it can be made by injecting test subjects with Globo H conjugate of the invention and then isolating hybridomas expressing antibodies having the desired sequence or functional characteristics.
- DNA encoding the monoclonal antibodies is readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of the monoclonal antibodies).
- the hybridoma cells serve as a preferred source of such DNA.
- the DNA may be placed into expression vectors, which are then transfected into host cells such as E. coli cells, simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. Recombinant production of antibodies will be described in more detail below.
- antibodies or antibody fragments can be isolated from antibody phage libraries generated using the conventional techniques known in the art; for example, the isolation of murine and human antibodies, respectively, using phage libraries.
- phage libraries generated using the conventional techniques known in the art; for example, the isolation of murine and human antibodies, respectively, using phage libraries.
- Subsequent publications describe the production of high affinity (nM range) human antibodies by chain shuffling, as well as combinatorial infection and in vivo recombination as a strategy for constructing very large phage libraries.
- these techniques are viable alternatives to traditional monoclonal antibody hybridoma techniques for isolation of monoclonal antibodies.
- the disclosure provides an isolated anti-Globo H antibody, comprising (i) a heavy chain variable region comprising an amino acid sequence having at least 85% identical to any of the amino acid sequences of SEQ ID NOs: 140 to 163, and (ii) a light chain variable region comprising an amino acid sequence having at least 80% identical to any of the amino acid sequence of SEQ ID NO: 164 to 199.
- the sequence identity as mentioned above is at least 90%, 91%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%.
- the present invention provides an isolated anti-Globo H antibody, comprising (i) a heavy chain variable region comprising an amino acid sequence having at least 85% identical to the amino acid sequences of SEQ ID NO: 147, and (ii) a light chain variable region comprising an amino acid sequence having at least 80% identical to the amino acid sequence of SEQ ID NO: 195.
- the present invention provides an isolated anti-Globo H antibody, comprising (i) a heavy chain variable region comprising an amino acid sequence consisting of SEQ ID NO: 147, and (ii) a light chain variable region comprising an amino acid sequence consisting of SEQ ID NO: 195 (MZ-2 antibody).
- nucleotides encoding the heavy chian variable region having the amino acid sequence of SEQ ID NO: 147 are as follows:
- nucleotides encoding the light chian variable region having the amino acid sequence of SEQ ID NO: 195 are as follows:
- the isolated anti-Globo H antibody of the presetn invention is a humanized or chimeric antibody or fragment thereof capable of specifically binding to Globo H.
- the disclosure provides a humanized anti-Globo H antibody or an antigen-binding portion thereof, comprising (i) a heavy chain variable region comprising an amino acid sequence having at least 85% identical to any of the amino acid sequences of SEQ ID NOs: 20 to 43, and (ii) a light chain variable region comprising an amino acid sequence having at least 80% identical to any of the amino acid sequence of SEQ ID NO: 44 to 79 and 200 to 235.
- the sequence identity as mentioned above is at least 90%, 91%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%.
- the disclosure provides a humanized anti-Globo H antibody or an antigen-binding portion thereof, comprising (i) a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 20 to 43, and (ii) a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 44 to 79 and 200 to 235.
- the humanized anti-Globo H antibody or an antigen-binding portion thereof comprises a heavy chain variable region comprising an amino acid sequence consisting of SEQ ID NO: 27, and a light chain variable region comprising an amino acid sequence consisting of SEQ ID NO: 75 (hMZ-2Lw antibody).
- the humanized anti-Globo H antibody or an antigen-binding portion thereof can comprise a heavy chain variable region comprising an amino acid sequence consisting of SEQ ID NO: 27, and a light chain variable region comprising an amino acid sequence consisting of SEQ ID NO: 231.
- the disclosure provides a humanized anti-Globo H antibody or an antigen-binding portion thereof, comprising (i) a heavy chain variable region comprising an amino acid sequence having at least 85% identical to any of the amino acid sequences of SEQ ID NOs: 80 to 103, and (ii) a light chain variable region comprising an amino acid sequence having at least 80% identical to any of the amino acid sequence of SEQ ID NOs: 104 to 139.
- the sequence identity as mentioned above is at least 90%, 91%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%.
- the disclosure provides a humanized anti-Globo H antibody or an antigen-binding portion thereof, comprising (i) a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 80 to 103, and (ii) a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 104 to 139.
- the humanized anti-Globo H antibody or an antigen-binding portion thereof can comprise a heavy chain variable region comprising an amino acid sequence consisting of SEQ ID NO: 90, and a light chain variable region comprising an amino acid sequence consisting of SEQ ID NO: 135 (MK1 antibody).
- a humanized antibody has one or more amino acid residues from a source that is non-human.
- the non-human amino acid residues are often referred to as "import” residues, and are typically taken from an "import” variable domain.
- Humanization can be performed generally following conventional method known in the art, by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Accordingly, such "humanized” antibodies are antibodies wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species.
- humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in non-human, for example, rodent antibodies.
- variable domains both light and heavy
- the choice of human variable domains, both light and heavy, to be used in making the humanized antibodies is very important to reduce antigenicity.
- the sequence of the variable domain of a rodent antibody is screened against the entire library of known human variable-domain sequences.
- the human sequence which is closest to that of the rodent is then accepted as the human framework (FR) for the humanized antibody.
- FR human framework
- Another method uses a particular framework derived from the consensus sequence of all human antibodies of a particular subgroup of light or heavy chains. The same framework may be used for several different humanized antibodies.
- humanized antibodies are prepared by a process of analysis of the parental sequences and various conceptual humanized products using three-dimensional models of the parental and humanized sequences.
- Three-dimensional immunoglobulin models are commonly available and are familiar to those skilled in the art.
- Computer programs are available which illustrate and display probable three-dimensional conformational structures of selected candidate immunoglobulin sequences. Inspection of these displays permits analysis of the likely role of the residues in the functioning of the candidate immunoglobulin sequence, i.e., the analysis of residues that influence the ability of the candidate immunoglobulin to bind its antigen.
- FR residues can be selected and combined from the recipient and import sequences so that the desired antibody characteristic, such as increased affinity for the target antigen(s), is achieved.
- the CDR residues are directly and most substantially involved in influencing antigen binding.
- the disclosure provides a chimeric anti-Globo H antibody or an antigen-binding portion thereof, comprising (i) a heavy chain variable region comprising an amino acid sequence having at least 85% identical to any of the amino acid sequences of SEQ ID NOs: 140-163 wherein the last third sequence V of the amino acid sequences is changed as I, and (ii) a light chain variable region comprising an amino acid sequence having at least 80% identical to any of the amino acid sequence of SEQ ID NO:164-199.
- the sequence identity as mentioned above is at least 90%, 91%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%.
- the present invention provides a chimeric anti-Globo H antibody, comprising (i) a heavy chain variable region comprising an amino acid sequence having at least 85% identical to the amino acid sequences of SEQ ID NO: 147 wherein the last third sequence V of the amino acid sequence is changed as I, and (ii) a light chain variable region comprising an amino acid sequence having at least 85% identical to the amino acid sequence of SEQ ID NO: 195.
- the present invention provides an isolated anti-Globo H antibody (cMZ-2), comprising (i) a heavy chain variable region comprising an amino acid sequence consisting of SEQ ID NO: 147 wherein the last third sequence V of the amino acid sequences is changed as I, and (ii) a light chain variable region comprising an amino acid sequence consisting of SEQ ID NO: 195.
- cMZ-2 isolated anti-Globo H antibody
- the production of the chimeric antibody can be produced according to conventional methods known in the art.
- Methods for producing chimeric antibodies are known in the art. See e.g., Morrison, Science 229:1202 (1985 ); Oi et al., BioTechniques 4:214 (1986 ); Gillies et al., (1989) J. Immunol. Methods 125:191-202 ; U.S. Pat. Nos. 5,807,715 ; 4,816,567 ; and 4,816,397 .
- techniques developed for the production of " chimeric antibodies” (Morrison et al., 1984, Proc. Natl. Acad. Sci.
- the constant domains of the light and heavy chains of, for example, a mouse monoclonal antibody can be substituted 1) for those regions of, for example, a human antibody to generate a chimeric antibody or 2) for a non-immunoglobulin polypeptide to generate a fusion antibody.
- the constant regions are truncated or removed to generate the desired antibody fragment of a monoclonal antibody.
- site-directed or high-density mutagenesis of the variable region can be used to optimize specificity, affinity, etc. of a monoclonal antibody.
- the present invention provides a pharmaceutical composition comprising an anti-Globo H antibody or an antigen-binding portion thereof.
- the present antibody can also be formulated into a pharmaceutical composition.
- the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.
- Administration of the anti-Globo H antibody or an antigen-binding portion thereof described herein can include formulation into pharmaceutical compositions or pharmaceutical formulations for parenteral administration, e.g., intravenous; mucosal, e.g., intranasal; ocular, or other mode of administration.
- the anti-Globo H antibody or an antigen-binding portion thereof described herein can be administered along with any pharmaceutically acceptable carrier compound, material, or composition which results in an effective treatment in the subject.
- a pharmaceutical formulation/composition for use in the methods described herein can contain an anti-Globo H antibody or an antigen-binding portion thereof as described herein in combination with one or more pharmaceutically acceptable carriers.
- phrases "pharmaceutically acceptable” refers to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
- pharmaceutically acceptable carrier means a pharmaceutically acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent, media, encapsulating material, manufacturing aid (e.g., lubricant, talc magnesium, calcium or zinc stearate, or steric acid), or solvent encapsulating material, involved in maintaining the stability, solubility, or activity of, an anti-Globo H antibody or an antigen-binding portion thereof as described herein.
- manufacturing aid e.g., lubricant, talc magnesium, calcium or zinc stearate, or steric acid
- solvent encapsulating material involved in maintaining the stability, solubility, or activity of, an anti-Globo H antibody or an antigen-binding portion thereof as described herein.
- Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient.
- excipient "carrier”, “pharmaceutically acceptable carrier”, or the like are used interchange
- the anti-Globo H antibody or an antigen-binding portion thereof as described herein can be specially formulated for administration of the compound to a subject in solid, liquid or gel form, including those adapted for the following: (1) parenteral administration, for example, by subcutaneous, intramuscular, intravenous or epidural injection as, for example, a sterile solution or suspension, or sustained-release formulation; (2) topical application, for example, as a cream, ointment, or a controlled-release patch or spray applied to the skin; (3) intravaginally or intrarectally, for example, as a pessary, cream or foam; (4) ocularly; (5) transdermally; (6) transmucosally; or (79) nasally. Additionally, a anti-Globo H antibody or an antigen-binding portion thereof as described herein can be implanted into a patient or injected using a drug delivery system.
- the therapeutically effective amount of the antibody for mice could be expressed as 0.8-100 mg/kg body weight.
- HED of the above-mentioned murine effective amount is about 0.65-81.5 mg/kg body weight.
- the therapeutically effective amount of the antibody can be at least 1 mg/kg.
- an initial candidate dosage for administration to a subject is an initial candidate dosage for administration to a subject, whether, for example, by one or more separate administrations, or by continuous infusion.
- a typical daily dosage might range from about 1 mg/kg to about 100 mg/kg or more, depending on the factors mentioned above.
- Typical dosages include, for example, 5 mg/kg, 10 mg/kg, 20 mg/kg, and 30 mg/kg.
- the treatment is sustained until, for example, the cancer is treated, as measured by the methods described above or known in the art.
- the disclosure provides a method of treating and/or preventing a cancer, comprising administering to a subject in need thereof a therapeutically effective amount of an anti-Globo H antibody or an antigen-binding portion thereof as described herein or a pharmaceutical composition comprising an anti-Globo H antibody or an antigen-binding portion thereof as described herein.
- the administration of the antibody or the pharmaceutical composition comprising the same to a subject confers passive protection to the subject and thereby provides the intended therapeutic effect to a cancer, such as tumor-associated carbohydrate-expressing cancer; preferably, breast cancer, ovarian cancer, pancreatic cancer, prostate cancer, colorectal cancer and lung cancer.
- a cancer such as tumor-associated carbohydrate-expressing cancer; preferably, breast cancer, ovarian cancer, pancreatic cancer, prostate cancer, colorectal cancer and lung cancer.
- the anti-Globo H antibody or an antigen-binding portion thereof as described herein or a pharmaceutical composition comprising an anti-Globo H antibody or an antigen-binding portion thereof as described herein is administered to a subject having a cancer to be inhibited by any mode of administration that delivers the agent systemically or to a desired surface or target, and can include, but is not limited to, injection, infusion, instillation, and inhalation administration.
- any mode of administration that delivers the agent systemically or to a desired surface or target
- anti-Globo H antibody or an antigen-binding portion thereof as described herein or a pharmaceutical composition comprising an anti-Globo H antibody or an antigen-binding portion thereof as described herein can be protected from inactivation in the gut, oral administration forms are also contemplated.
- injection includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intraventricular, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, sub capsular, subarachnoid, intraspinal, intracerebro spinal, and intrasternal injection and infusion.
- the anti-Globo H antibody or an antigen-binding portion thereof as described herein or a pharmaceutical composition comprising an anti-Globo H antibody or an antigen-binding portion thereof as described herein for use in the methods described herein are administered by intravenous infusion or injection.
- parenteral administration and “administered parenterally” as used herein, refer to modes of administration other than enteral and topical administration, usually by injection.
- systemic administration refers to the administration of the bispecific or multispecific polypeptide agent other than directly into a target site, tissue, or organ, such as a tumor site, such that it enters the subject's circulatory system and, thus, is subject to metabolism and other like processes.
- the methods provided herein for inhibiting or treating cancer in subject having or at risk for cancer by administering to the subject a therapuetically effective amount of an anti-Globo H antibody or an antigen-binding portion thereof as described herein or a pharmaceutical composition comprising an anti-Globo H antibody or an antigen-binding portion thereof as described herein can, in some embodiments, further comprise administration one or more additional treatments such as angiogenic inhibitors, chemotherapy, radiation, surgery, or other treatments known to those of skill in the art to prevent and/or treat cancer.
- 1x10 8 of single cell suspended splenocytes were mixed with 2x10 7 of FO cells, and cell fusion was performed in 1 ml of 50% PEG 1500 solution (Roche) at 37°C followed by drop-wise addition of 13 ml of warmed RPMI medium (Gibco). Fused cells were centrifuged and washed twice with complete medium. Cells were then resuspended in complete medium with 1x BM-Conditioned H1 Hybridoma cloning supplement (Roche) and seeded into 96-well plates.
- 1x10 8 splenocytes and 2x10 7 FO cells were mixed together, and chemical cell fusion was performed as describe above. After cell fusion, cells were cultured in RPMI 1640 medium containing 1xHAT medium (Gibco) for further selection.
- Mmonoclonal antibody-producing hybridoma cell lines were screened through limited dilution by ELISA assay on plate coated with Globo H-biotin antigen. Five clones (named MZ-1 to MZ-5, respectively) capable of secreting high-titers of anti-Globo H IgG or IgM antibodies were obtained.
- Supernatants from these hybridoma lines were also subjected to cell binding assay. Briefly, 100 ⁇ l of the supernatant from the hybridoma culture was incubated with 2x105 of MCF-7 cells and then analyzed by flow cytometry with appropriate fluorescent secondary antibody mentioned below. The cells were washed once with 2 ml of 1x PBS. After centrifugation, the wash buffer was discarded and cells were resuspended in 100 ⁇ l of 1:100 diluted PE anti-mouse IgG-Fc (Jackson immunoresearch) or 100 ⁇ l of 1:100 diluted PE anti-mouse IgM (eBioscience) and incubated again at room temperature for 20 minutes.
- PE anti-mouse IgG-Fc Jackson immunoresearch
- PE anti-mouse IgM eBioscience
- Variable regions of heavy and light chains of MZ-2 antibody were first cloned to human IgG1 and kappa chain conserved region expression vectors to form mouse-human chimeric MZ-2 (cMZ-2).
- the cMZ-2 antibody has been gone through humanization by CDR-grafting based on structure analysis and sequence homology.
- the humanized MZ-2 antibody (hMZ-2) could be readily expressed as a recombinant IgG in mammalian cells and retains the antigen-binding affinity and specificity of the parent mouse antibody.
- the humanized construct was further transfected into FO cells by electroporation and selected by associated antibiotics to generate stable expression clones.
- Antibodies produced from the FO cells were checked by flow cytometry analysis.
- 1x06 of hMZ-2 expression FO cells were first i.p. injected into NOD/SCID mice. Ascites from these mice were harvest after 2 weeks and passed through protein G agarose column to purify the generated antibody. The thus-obtained hMZ-2 antibodies were sequenced.
- the hMZ-2 antibody, hMz-2Lw (variable region of heavy chain: SEQ ID No. 27; variable region of light chain: SEQ ID No. 75 and MK1 (variable region of heavy chain: SEQ ID No. 90; variable region of light chain: SEQ ID No. 135), were used in the following examples.
- Ovarian cancer tissues were obtained under the approval of IRB and patient consent. Ovarian cancer tissues were digested by MASC Tumor Dissociation kit (MASC, 130-095-929). The single cell suspension was stained with MZ-2 monoclonal antibody (10 ⁇ g/ml ; 100 ⁇ l) for 30 minutes at 4°C., and stained with secondary antibody anti-mouse IgG1 PE(1:50; eBioscience, 2-405-82), then fixed with 4% paraformaldehyde for 1 min at RT.
- MASC Tumor Dissociation kit MASC Tumor Dissociation kit
- Biotinylated-carbohydrates were conjugated on BD Cytometric Beads via Avidin by Functional Bead Conjugation Buffer Set (BD).
- 75 ⁇ L of the functional beads were sonicated and incubated with 1.9 ⁇ L of 1M DTT at room temperature for 1 hr.
- 20 uL of each biotin-carbohydrate (0.2mg/mL) was mixed with 90 ⁇ g of maleimide activated neutrAvidin (1mg/mL in coupling buffer; Pierce) and incubated at room temperature for 1 hr.
- the beads were washed 3 times with 1 mL of coupling buffer and resuspended in 20 ⁇ L of coupling buffer.
- the carbohydrate were then mixed with designed beads and incubated with further one hour. 2 ⁇ L of N-Ethylmaleimide (2mg/mL on DMSO, Pierce) was then added into the conjugated beads and incubated for further 15 min. After 3 time wash, the beads were suspended in 500 ⁇ L of storage buffer and ready for use.
- each set of carbohydrate-conjugated beads were mixed and diluted to 1:50 of each. 50 ⁇ L of bead mixture was then transfer to V buttom 96-well plate, and mixed with 50 ⁇ L of 1:1000 diluted serum or 1 ⁇ g/mL of MZ-2 antibody. After incubation for 30 min, the beads were washed with 150 ⁇ L of wash buffer and further stained with 100 ⁇ L of PE-conjugated 2Ab (Jackson Immunoresearch). The binding of anti-Globo H antibody were detected by FACS.
- Figure 3 show the specificity of MZ-2 antibody is indicated by the fact that MZ-2 and chimeric MZ-2 antibodies only bind to Globo H-conjugated beads, but not SSEA3- or SSEA4-conjugated beads.
- FIG. 4A The 3-D structure of variable regions in original and humanized MZ-2 clones were simulated by Prediction of Immunoglobulin Structure online program.
- Figures 4A and B show the simulation of protein folding of mouse MZ-2 monoclonal antibody ( Fig. 4A ) and humanized MZ-2 monoclonal antibodies ( Fig. 4B ).
- the binding affinity of anti-Globo H antibody was detected by Biolayer interferometry using FortrBio OcTet system. Briefly, the sensors were first soaked in 20 ⁇ M of biotinylated Globo H to coat Globo H on their surface.
- the MZ-2 clone (mMZ-2), mouse-human chimerical MZ-2 clone (cMZ-2), and humanized MZ-2 clones (hMZ-2L, MK-1or hMZ-2Lw) were serially diluted into 1333, 444.4, 148.1, 49.4 and 16.5 nM, and incubated with Globo H coated sensors separately. 10mM of Glycine (pH 1.5) was used as Regeneration buffer.
- Figures 5A and B show biacore full binding kinetic analysis of MZ-2 antibodies were carried out. Detailed binding kinetic parameters (association rate, ka, dissociation rate, kd, and affinity constant, KD) were determined by full kinetic analysis. Sensograms for each antibody are shown. The KD values of three humanized MZ-2 antibodies (hMZ-2L (see Fig. 5C ), MK-1 (see Fig. 5D ) and hMZ-2Lw (see Fig. 5E )) and chimeric MZ-2 (cMZ-2) antibody (see Fig. 5B ) are similar.
- MCF-7, TOV21G Globo H(+), and HPAC cells were adjusted to 2 x 106 cells/ mL in RPMI 1640 medium and aliquot 50 ⁇ L of diluted cells into flow tubes.
- the chimeric MZ-2 antibody was diluted to 2x designed concentration in RPMI 1640 medium and aliquot 50 ⁇ L to each flow tube with cancer cells.
- Human IgG (Fitzgerald, 31-AI06) was diluted into the same concentration as a control. After 15 min, 100 ⁇ L of normal human serum from healthy human donor was added into each tube and incubated at 37°C for 2hr. The cells were washed once with complete medium and resuspended in 200 ⁇ L of complete medium with 0.5 ⁇ g/mL propidium iodide. The percentage of dead cells was analyzed using FACS.
- FIGS 9A and B and Figures. 10A and B respectively summarizes the antigen-dependent cell-mediated cytotoxicity (ADCC) activity of the present hMZ-2Lw and MK1 antibodies on MCF-7 cells (breast cancer cell line) and TOV21G cells (ovarian cancer cell line).
- ADCC antigen-dependent cell-mediated cytotoxicity
- mice For establishing an intra-peritoneal ovarian tumor model, 1x10 6 of TOV21G cells were intraperitoneally (i.p.) injected into 5-week-old female NU/NU mice (BioLASCO Taiwan). Two days later, mice were divided into 4 groups and administered with either 100 ⁇ g (at a therapeutic dose of 5 mg/kg) of Human IgG, anti-GloboH antibodies hMZ-2Lw or MK1 twice a week through tail vein (i.v.) route. Untreated mice were set as control. To monitor the tumor growth, tumor bearing mice were i.p.
- Migrated cells through the membrane were fixed with 4% formaldehyde and stained with crystal violate. The numbers of migrated cells were counted by tissue scanner (TissueGnostics).
- Figure 14 shows that MZ-2 antibody inhibits migration of Globo H-expressing TOV21G cells.
- Globo H-expressing TOV21G cells were mixed with 5 ⁇ g of mouse IgG1 isotype (eBioscience) or MZ-2 antibody (hMZ-2Lw) in 0.5 mL of culture medium and incubated at 37°C for 15 min. Those cells were then washed three times with 1x PBS, and resuspended to 4 ⁇ 10 5 cells/mL in culture medium. One hundred micro liters of cells were transferred into a well of wound healing culture-inserts (Ibid Cat# 80241) in a 24-well plate and incubated for 8 hours in CO 2 incubator. Cells without antibody treatment, or Globo H-negative TOV21G cells were used as controls.
- the antibodies of the invention having the heavy chain variable regions and the light chain variable regions as described herein were subjected to the binding affinity assay of Example 2, association and dissociation assay of Example 5, CDC assay of Example 6, ADCC assay of Example 7 and anti-tumor assay of Example 8 and show similar results to cMZ-2 antobody, hMZ-2Lw antibody and MK-1 antibody.
- the KD value of the antibody having a heavy chain variable region of SEQ ID NO: 27, and a light chain variable region of SEQ ID NO: 231 is in the range of 1x 10 -7 to 1x 10 -10 nM.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
- The present invention relates to the field of immunotherapy of cancer. More particularly, the disclosed invention relates to an antibody against an immunogenic glycopeptide, a pharmaceutical composition comp comprising the antibody and to the antibody for use cancer therapy.
- Globo H is a hexasaccharide and belongs to a large number of tumor-associated carbohydrate antigens that are overexpressed on the surface of various epithelial cancer cells, including breast, colon, ovarian, pancreatic, lung, and prostate cancer cells. The aberrant expression of Globo H renders it an attractive candidate for immunotherapy and the development of cancer vaccines for Globo H-positive cancers.
- However, like most carbohydrate antigens, Globo H is often tolerated by the immune system, and consequently, the immunogenicity induced by Globo H is limited. Further, the production of antibody against a specific immunogen typically involves the cooperative interaction of two types of lymphocytes, B-cells and helper T-cells. Yet, Globo H alone cannot activate helper T-cells, which also attributes to the poor immunogenicity of Globo H. Accordingly, the immunization with Globo H is often typified by low titer of immunoglobulin M (IgM) and failure to class switch to immunoglobulin G (IgG), as well as ineffective antibody affinity maturation.
- Various approaches have been developed to address the above-mentioned deficiencies. In certain researches, foreign carrier proteins or peptides having T-epitopes (such as keyhole limpet hemocyanin (KLH) or detoxified tetanus toxoid (TT)) have been conjugated with carbohydrate antigens hoping to enhance the immunogenicity of the carbohydrate antigens.
US 20010048929 provided a multivalent immunogenic molecule, comprising a carrier molecule containing at least one functional T-cell epitope, and multiple different carbohydrate fragments each linked to the carrier molecule and each containing at least one functional B-cell epitope, wherein said carrier molecule imparts enhanced immunogenicity to said multiple carbohydrate fragments and wherein the carbohydrate fragment is Globo H, LeY or STn.US 20120328646 provides a carbohydrate based vaccine containing Globo H (B cell epitope) chemically conjugated to the immunogenic carrier diphtheria toxin cross-reacting material 197 (DT-CRM 197) (Th epitope) via a p-nitrophenyl linker, which provides immunogenicity in breast cancer models, showing delayed tumorigenesis in xenograft studies.US 20120263749 relates to a polyvalent vaccine for treating cancer comprising at least two conjugated antigens selected from a group containing glycolipid antigen such as Globo H, a Lewis antigen and a ganglioside, polysaccharide antigen, mucin antigen, glycosylated mucin antigen and an appropriate adjuvant. - Nonetheless, conjugation of carbohydrates to a carrier protein poses several new problems. According to Ingale et al., the foreign carrier protein and the linker for attaching the carrier protein and the carbohydrate may elicit strong B-cell responses, thereby leading to the suppression of an antibody response against the carbohydrate epitope (Ingale S. et al. Robust immune responses elicited by a fully synthetic three-component vaccine. Nat Chem Biol. 2007 Oct;3(10):663-7 . Epub 2007 Sep 2). Furthermore, Ingale et al. also indicated that the conjugation chemistry is difficult to control, resulting in conjugates with ambiguities in composition and structure, which may affect the reproducibility of an immune response. Considering the above-mentioned factors, Ingale et al. concluded that it is not surprising that preclinical and clinical studies using carbohydrate-protein conjugates have led to mixed results. For example, Kuduk et al. taught that the immunization with a trimeric cluster of Tn-antigens conjugated to KLH in the presence of the adjuvant QS-21 elicited modest titers of IgG antibodies in mice (Kuduk SD, et al. Synthetic and immunological studies on clustered modes of mucin-related Tn and TF O-linked antigens: the preparation of a glycopeptide-based vaccine for clinical trials against prostate cancer. J Am Chem Soc. 1998;120:12474-12485 ); while Slovin et al. taught that the same vaccine gave low median IgG and IgM antibody titers in a clinical trial of relapsed prostate cancer patients (Slovin SF, et al. Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with alpha-N-acetylgalactosamine-O-serine/threonine conjugate vaccine. J Clin Oncol. 2003;21:4292-4298 ).
- Moreover, for cancer patients with hypoimmune status; particular in patients receiving chemotherapy or radiation therapy, as well as late-stage cancer patients, the efficacy of active immune intervention is often limited, for these patients may not be able to produce sufficient antibodies to elicit the anti-tumor effect.
- In view of the foregoing, there exists a need in the art for developing alternative strategies for improving the immunization and/or therapeutic efficacy of carbohydrate-based vaccines.
- Antibodies binding Globo H are known in the art, as illustrated by JUNG-TUNG HUNG ET AL: "Abstract 2529: A monoclonal anti-Globo H antibody, VK9 can mediate CDC/ADCC and inhibit adhesion of Globo H + cancer cells to extracellular matrix", CANCER RESEARCH, vol. 72, no. 8 Supplement, 15 April 2012 (2012-04-15), & 103RD ANNUAL MEETING OF THE AMERICAN-ASSOCIATION-FOR-CANCER-RESEARCH; CHICAGO, IL, USA; MARCH 31 -APRIL 04, 2012
- The invention to which this specification pertains is defined by the claims.
- The following presents a simplified summary of the disclosure in order to provide a basic understanding to the reader. This summary is not an extensive overview of the disclosure and it does not identify key/critical elements of the present invention or delineate the scope of the present invention. Its sole purpose is to present some concepts disclosed herein in a simplified form as a prelude to the more detailed description that is presented later.
- The present disclosure is directed to an antibody which specifically binds to Globo H according to any of the above-mentioned aspects of the present disclosure.
- According to certain aspects, the antibody is a monoclonal antibody.
- According to optional aspects, the antibody is a chimeric or humanized antibody.
- In still another aspect, the present disclosure is directed to a pharmaceutical composition for treating a cancer in a subject in need thereof.
- According to one aspect of the present disclosure, the pharmaceutical composition comprises (1) a therapeutically effective amount of the antibody according to any of the above-mentioned aspects of the present disclosure, and optionally (2) a pharmaceutically acceptable carrier.
- In still yet another aspect, the present disclosure is directed to a method of treating a cancer in a subject in need thereof.
- According to aspects of the present disclosure, the method includes administering to the subject the pharmaceutical composition the antibody or pharmaceutical composition according to any of the above-mentioned aspects of the present disclosure.
-
-
Figures 1A to E illustrate results of cell binding assay (A: Isotype; B: VK9; C: MZ-2; D: Control serum; E: α-Globo H serum). -
Figures 2 illustrate the binding affinity of anti-Globo H IgG antibody to primary ovarian cancer cells according to a few working examples of the present disclosure. -
Figure 3 is a FACS graph illustrating the result of a serial glycan-bead binding analysis, according to one working example of the present disclosure. -
Figures 4A and B shows the simulation of protein folding of anti-Globo H IgG antibody, according to one working example of the present disclosure (A: Mouse MZ-2 monoclonal antibody; B: Humanized MZ-2 monoclonal antibody). -
Figures 5A to E show the binding affinity of anti-Globo H IgG antibody, representing the association and Dissociation curve fitting and dissociation constant, according to one working example of the present disclosure (A: mMZ-2; B: cMZ-2; C:hMZ-2L; D: MK-1; E: hMZ-2Lw). -
Figure 6 shows that the human serum containing more than 1.6 µg/ml of hMZ-2Lw antibody elicited complement-dependent cytotoxicity in breast cancer, MCF-7 cells. -
Figure 7 shows that hMZ-2Lw antibody in a concentration higher than about 10 and 20µg/ml resulted in a dose-dependent cytotoxicity in human ovarian cancer cell line TOV21G. -
Figure 8 shows that hMZ-2Lw antibody in a concentration higher than about 10 and 20µg/ml resulted in a dose-dependent cytotoxicity in human pancreatic cancer cell line, HPAC. -
Figure 9A and B show antigen-dependent cell-mediated cytotoxicity (ADCC) activity of the present hMZ-2Lw and MK1 antibodies on MCF-7 cells (breast cancer cell line). -
Figures.10A and B show antigen-dependent cell-mediated cytotoxicity (ADCC) activity of the present hMZ-2Lw and MK1 antibodies on TOV21G cells (ovarian cancer cell line). -
Figure 11 shows administration of both hMZ-2Lw and MK1 antibodies significantly inhibit the tumor growth, while control IgG antibody did not substantially affect the tumor growth. -
Figure 12 shows results of hMZ-2 antibody in breast cancer subcutaneous model MCF-7 cell. -
Figures 13A and B shows the results of hMZ-2 antibody in pancreatic cancer subcutaneous model HPAC cell. (A: Photographs of tumors; B: Reduction of tumor size) -
Figure 14 shows that MZ-2 antibody inhibits migration of Globo H-expressing TOV21G cells. -
Figure 15 shows that MZ-2 antibody inhibits migration of Globo H-expressing TOV21G cells. - The present invention is based, at least, on the finding that recombinant antibodies specifically bind to Globo H for treating cancer expression tumor-associated carbohydrate antigens.
- Unless otherwise defined herein, scientific and technical terminologies employed in the present disclosure shall have the meanings that are commonly understood and used by one of ordinary skill in the art. Unless otherwise required by context, it will be understood that singular terms shall include plural forms of the same and plural terms shall include the singular. Specifically, as used herein and in the claims, the singular forms "a" and "an" include the plural reference unless the context clearly indicates otherwise. Also, as used herein and in the claims, the terms "at least one" and "one or more" have the same meaning and include one, two, three, or more.
- Notwithstanding that the numerical ranges and parameters setting forth the broad scope of the invention are approximations, the numerical values set forth in the specific examples are reported as precisely as possible. Any numerical value, however, inherently contains certain errors necessarily resulting from the standard deviation found in the respective testing measurements. Also, as used herein, the term "about" generally means within 10%, 5%, 1%, or 0.5% of a given value or range. Alternatively, the term "about" means within an acceptable standard error of the mean when considered by one of ordinary skill in the art. Other than in the operating/working examples, or unless otherwise expressly specified, all of the numerical ranges, amounts, values and percentages such as those for quantities of materials, durations of times, temperatures, operating conditions, ratios of amounts, and the likes thereof disclosed herein should be understood as modified in all instances by the term "about." Accordingly, unless indicated to the contrary, the numerical parameters set forth in the present disclosure and attached claims are approximations that can vary as desired. At the very least, each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques.
- The term "antigen" as used herein is defined as a substance capable of eliciting an immune response. Said immune response may involve either antibody production, or the activation of specific immunologically-competent cells, or both. As used herein, the term "immunogen" refers to an antigen capable of inducing the production of an antibody. Also, the term "immunogenicity" generally refers to the ability of an immunogen or antigen to stimulate an immune response.
- The term "epitope" refers to a unit of structure conventionally bound by an immunoglobulin VH/VL pair. An epitope defines the minimum binding site for an antibody, and thus represent the target of specificity of an antibody.
- The term "antibody" as used herein refers to a whole antibody molecule or a fragment, variant or derivative thereof, which is capable of recognizing or binding to an antigen. Most natural antibodies have two heavy chains and two light chains linked to each other by disulfide bonds. The light chain includes a variable domain (VL) and a constant domain (CL); while the heavy chain includes a variable domain (VH) and three constant domains (CHI, CH2 and CH3, collectively referred to as CH). The variable regions of both light (VL) and heavy (VH) chains determine binding recognition and specificity to the antigen. The VH and VL regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDR), interspersed with regions that are more conserved, termed framework regions (FR). Each VH and VL is, composed of three CDRs and four FRs arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The constant region domains of the light (CL) and heavy (CH) chains confer important biological properties such as antibody chain association, secretion, trans-placental mobility, complement binding, and binding to Fc receptors (FcR).
- As used herein, "antibody variable domain" refers to the portions of the light and heavy chains of antibody molecules that include amino acid sequences of Complementarity Determining Regions (CDRs; i.e., CDR1, CDR2, and CDR3), and Framework Regions (FRs). According to the methods used herein, the amino acid positions assigned to CDRs and FRs can be defined according to Kabat (Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, Md., 1987 and 1991)). Amino acid numbering of antibodies or antigen binding fragments is also according to that of Kabat.
- As used herein, the term "Complementarity Determining Regions" (CDRs), i.e., CDR1, CDR2, and CDR3) refers to the amino acid residues of an antibody variable domain the presence of which are necessary for antigen binding. Each variable domain typically has three CDR regions identified as CDR1, CDR2 and CDR3. H-CDR refers to the CDR of the heavy chain and L-CDR refers to the CDR of the light chain.
- As used herein, the term "monoclonal antibody" refers to an antibody molecule obtained from a single type of antibody-producing cells.
- The term "chimeric antibody" refers to an antibody comprising a variable region from one source or species and at least a portion of a constant region derived from a different source or species, usually prepared by recombinant DNA techniques. It is preferred that the CDRs of a chimeric antibody have one origin, while the remainder of the antibody has a different origin. In particular, in the present invention the chimeric antibody may be a humanized antibody in which the antigen binding sequences/variable domains of a non-human antibody have been grafted onto human antibody framework regions.
- As used herein, the term "humanized antibody" refers to forms of antibodies that contain sequences from non-human (e.g., murine) antibodies as well as human antibodies. Such antibodies contain minimal sequence derived from non-human immunoglobulin. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the hypervariable loops correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin sequence. The humanized antibody optionally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. The humanized forms of rodent antibodies will essentially comprise the same CDR sequences of the parental rodent antibodies, although certain amino acid substitutions may be included to increase affinity, increase stability of the humanized antibody, or for other reasons. However, as CDR loop exchanges do not uniformly result in an antibody with the same binding properties as the antibody of origin, changes in framework residues (FR), residues involved in CDR loop support, might also be introduced in humanized antibodies to preserve antigen binding affinity.
- Unless specified otherwise, in the peptide notation used herein, the left-hand direction is the amino-terminal (N-terminal) direction and the right-hand direction is the carboxy-terminal (C-terminal) direction, in accordance with standard usage and convention.
- "Percentage (%) amino acid sequence identity" with respect to the amino acid sequences identified herein is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the specific polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percentage sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. For purposes herein, sequence comparison between two amino acid sequences was carried out by computer program Blastp (protein-protein BLAST) provided online by Nation Center for Biotechnology Information (NCBI). Specifically, the percentage amino acid sequence identity of a given amino acid sequence A to a given amino acid sequence B (which can alternatively be phrased as a given amino acid sequence A that has a certain % amino acid sequence identity to a given amino acid sequence B) is calculated by the formula as follows:
- As discussed herein, minor variations in the amino acid sequences of proteins/polypeptides are contemplated as being encompassed by the present disclosure, providing that the variations in the amino acid sequence maintain at least 80% such as at least, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% and 99%. In particular, conservative amino acid replacements are contemplated. Conservative replacements are those that take place within a family of amino acids that are related in their side chains. Genetically encoded amino acids are generally divided into families: (1) acidic aspartate, glutamate; (2) basic lysine, arginine, histidine; (3) nonpolar alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan; and (4) uncharged polar glycine, asparagine, glutamine, cysteine, serine, threonine, tyrosine. More preferred families are: serine and threonine are aliphatic-hydroxy family; asparagine and glutamine are an amide-containing family; alanine, valine, leucine and isoleucine are an aliphatic family; and phenylalanine, tryptophan, and tyrosine are an aromatic family. For example, it is reasonable to expect that an isolated replacement of a leucine with an isoleucine or valine, an aspartate with a glutamate, a threonine with a serine, or a similar replacement of an amino acid with a structurally related amino acid will not have a major effect on the binding or properties of the resulting molecule, especially if the replacement does not involve an amino acid within a framework site. Whether an amino acid change results in a functional peptide can readily be determined by assaying the specific activity of the polypeptide derivative. Fragments or analogs of proteins/polypeptides can be readily prepared by those of ordinary skill in the art. Preferred amino- and carboxy-termini of fragments or analogs occur near boundaries of functional domains.
- As used herein, "antibody mutant" or "antibody variant" refers to an amino acid sequence variant of the species-dependent antibody wherein one or more of the amino acid residues of the species-dependent antibody have been modified. Such mutants necessarily have less than 100% sequence identity or similarity with the species-dependent antibody. In one embodiment, the antibody mutant will have an amino acid sequence having at least 75% amino acid sequence identity or similarity with the amino acid sequence of either the heavy or light chain variable domain of the species-dependent antibody, more preferably at least 80%, more preferably at least 85%, more preferably at least 90%, and most preferably at least 95%. Identity or similarity with respect to this sequence is defined herein as the percentage of amino acid residues in the candidate sequence that are identical (i.e., same residue) or similar (i.e., amino acid residue from the same group based on common side-chain properties, see below) with the species-dependent antibody residues, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity. None of N-terminal, C-terminal, or internal extensions, deletions, or insertions into the antibody sequence outside of the variable domain shall be construed as affecting sequence identity or similarity.
- As used herein, the term "antigen-binding portion" of an antibody (or simply "antigen portion"), refers to full length or one or more fragments of an antibody that retain the ability to specifically bind to an antigen. It has been shown that the antigen-binding function of an antibody can be performed by fragments of a full-length antibody. Examples of binding fragments encompassed within the term "antigen-binding portion" of an antibody include a Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CH1 domains; a F(ab)2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; a Fd fragment consisting of the VH and CH1 domains; a Fv fragment consisting of the VL and VH domains of a single arm of an antibody; a dAb fragment (Ward et al., 1989 Nature 341:544-546), which consists of a VH domain; and an isolated complementarity determining region (CDR), or any fusion proteins comprising such antigen-binding portion.
- Unless contrary to the context, the term "treatment" are used herein broadly to include a preventative (e.g., prophylactic), curative, or palliative measure that results in a desired pharmaceutical and/or physiological effect. Preferably, the effect is therapeutic in terms of partially or completely curing or preventing cancer. Also, the terms "treatment" and "treating" as used herein refer to application or administration of the present immunogenic glycopeptide, antibody, or pharmaceutical composition comprising any of the above to a subject, who has cancer, a symptom of cancer, a disease or disorder secondary to cancer, or a predisposition toward cancer, with the purpose to partially or completely alleviate, ameliorate, relieve, delay onset of, inhibit progression of, reduce severity of, and/or reduce incidence of one or more symptoms or features of cancer. Generally, a "treatment" includes not just the improvement of symptoms or decrease of markers of the disease, but also a cessation or slowing of progress or worsening of a symptom that would be expected in absence of treatment. The term "treating" can also be used herein in a narrower sense which refers only to curative or palliative measures intended to ameliorate and/or cure an already present disease state or condition in a patient or subject.
- The term "preventing" as used herein refers to a preventative or prophylactic measure that stops a disease state or condition from occurring in a patient or subject. Prevention can also include reducing the likelihood of a disease state or condition from occurring in a patient or subject and impeding or arresting the onset of said disease state or condition.
- The term "effective amount" as used herein refers to the quantity of a component which is sufficient to yield a desired response. Effective amount may be expressed, for example, in grams, milligrams or micrograms or as milligrams per kilogram of body weight (mg/kg). The term also refers to an amount of a pharmaceutical composition containing an active component or combination of components. The specific effective or sufficient amount will vary with such factors as the particular condition being treated, the physical condition of the patient (e.g., the patient's body mass, age, or gender), the type of mammal or animal being treated, the duration of the treatment, the nature of concurrent therapy (if any), and the specific formulations employed and the structure of the compounds or its derivatives.
- As used herein, the term "therapeutically effective amount" refers to the quantity of an active component which is sufficient to yield a desired therapeutic response. A therapeutically effective amount is also one in which any toxic or detrimental effects of the compound or composition are outweighed by the therapeutically beneficial effects.
- As used herein, a "pharmaceutically acceptable carrier" is one that is suitable for use with the subjects without undue adverse side effects (such as toxicity, irritation, and allergic response) commensurate with a reasonable benefit/risk ratio. Also, each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the pharmaceutical composition. The carrier can be in the form of a solid, semi-solid, or liquid diluent, cream or a capsule. The carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation, and is selected to minimize any degradation of the active agent and to minimize any adverse side effects in the subject.
- The term "subject" refers to a mammal including the human species that is treatable with antibody. The term "subject" is intended to refer to both the male and female gender unless one gender is specifically indicated.
- Unless defined otherwise, all technical and scientific terms used herein have the same meaning as those commonly understood to one of ordinary skill in the art to which this invention pertains. Although any known methods, devices, and materials may be used in the practice or testing of the invention, the methods, devices, and materials in this regard are described herein.
- Provided herein are novel recombinant anti-Globo H antibodies and anti-Globo H-binding peptides specifically binding to Globo H or its derivatives, and methods of their use in anti-tumor immunotherapies, such as the treatment of cancer. Once bound to a cancer antigen, antibodies can induce antibody-dependent cell-mediated cytotoxicity, activate the complement system, and prevent a receptor interacting with its ligand (such as Globo H). In one embodiment, the compositions comprising the anti-Globo H-binding peptides or anti-Globo H antibodies described herein are useful in anti-cancer therapies. Furthermore, the compositions comprising the anti-Globo H-binding peptides or anti-Globo H antibodies can combine with an additional anti-tumor agent. In particular, the present embodiments provide the complementarity determining region (CDR) sequences of specific anti-Globo H antibodies, which can be used in a variety of anti-Globo H-binding peptides. In particular, the present invention provides a humanized or chimeric antibody or an antigen-binding fragment thereof capable of binding to Globo H or its derivatives.
- In one aspect, the present disclosure provides an isolated anti-Globo H antibody or an antigen-binding portion thereof, comprising at least one of a heavy chain complementarity determining region 1 (H-CDR1) consisting of the amino acid residues of GFSLSTFDMGVG (SEQ ID NO: 1), GSSLSTFDVGVG (SEQ ID NO: 2), GFSLGTFDLGIG (SEQ ID NO: 3), GFSLSTFDLGIG (SEQ ID NO: 4) or a variant having amino acid sequence with at least 80% identity to any of SEQ ID NOs: 1 to 4; a heavy chain CDR2 (H-CDR2) consisting of the amino acid residues of HIWWDDDKYYNPA (SEQ ID NO:5), HIWGDDDKYYNPA (SEQ ID NO: 6) or a variant having amino acid sequence with at least 80% identity to any of SEQ ID NOs: 5 and 6; and a heavy chain CDR3 (H-CDR3) consisting of the amino acid residues of LYGNYLTSFYCDY (SEQ ID NO: 7), or LSGNYLTSFYCDY (SEQ ID NO: 8), LYGNYLRSYYCDY (SEQ ID NO: 9) or a variant having amino acid sequence with at least 80% identity to any of SEQ ID NOs: 7 to 9; and at least one of a light chain CDR1 (L-CDR1) consisting of the amino acid residues of SASSSVSYMH (SEQ ID NO: 10), SASSRVSYMH (SEQ ID NO:11), SARSSVSYMH (SEQ ID NO:12), RASSSVSYMH (SEQ ID NO:13) or a variant having amino acid sequence with at least 80% identity to any of SEQ ID NOs: 10 to 13; a light chain CDR2 (L-CDR2) consisting of the amino acid residues of ATSNLAS (SEQ ID NO:14), WTSDRYS (SEQ ID NO:15), DTSKLAS (SEQ ID NO:16) or a variant having amino acid sequence with at least 80% identity to any of SEQ ID NOs: 14 to 16; and a light chain CDR3 (L-CDR3) consisting of the amino acid residues QQWSSNPFT (SEQ ID NO: 17), QQWSSNPLT (SEQ ID NO: 18), QQHLHIPYT (SEQ ID NO: 19) or a variant having amino acid sequence with at least 80% identity to any of SEQ ID NOs: 17 to 19; such that said isolated antibody or antigen-binding portion thereof binds to Globo H. Preferably, the sequence identity as mentioned above is at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%.
- In a further embodiment, the present disclosure provides an isolated anti-Globo H antibody or an antigen-binding portion thereof, comprising (i) a heavy chain variable region comprising a heavy chain variable region comprising H-CDR1 selected from the group consisting of SEQ ID NOs: 1 to 4, H-CDR2 selected from the group consisting of SEQ ID NOs: 5 and 6 and H-CDR3 selected from the group consisting of SEQ ID NOs: 7 to 9, and (ii) light chain variable regions comprising L-CDR1 selected from the group consisting of SEQ ID NOs: 10 to 13, L-CDR2 selected from the group consisting of SEQ ID NOs: 14 to 16 and L-CDR3 selected from the group consisting of SEQ ID NOs: 17 to 19. Preferably, H-CDR1 is SEQ ID NO:3; H-CRD2 is SEQ ID NO:5; H-CDR3 is SEQ ID NO:8; L-CDR1 is SEQ ID NO:10; L-CDR2 is SEQ ID NO:16; and L-CDR3 is SEQ ID NO:18.
- Insofar as the invention is concerned, H-CDR1 has the amino acid sequence of SEQ ID NO:3 or SEQ ID NO:4; H-CDR2 has the amino acid sequence of SEQ ID NO:5; H-CDR3 has the amino acid sequence of SEQ ID NO: 8; L-CDR1 has the amino acid sequence of SEQ ID NO:12; L-CDR2 has the amino acid sequence of SEQ ID NO:16 and L-CDR3 has the amino acid sequence of SEQ ID NO:18.
- In one aspect, the present disclosure provides a heavy chain variable region comprising a heavy chain variable region comprising H-CDR1 selected from the group consisting of SEQ ID NOs: 1 to 4, H-CDR2 selected from the group consisting of SEQ ID NOs: 5 and 6 and H-CDR3 selected from the group consisting of SEQ ID NOs: 7 to 9. In the present invention the heavy chain variable region can comprise SEQ ID NO: 3 as H-CDR1, SEQ ID NO: 5 H-CDR2 and SEQ ID NO: 8 as H-CDR3.
- In one aspect, the present disclosure provides a light chain variable region comprising L-CDR1 selected from the group consisting of SEQ ID NOs: 10 to 13, L-CDR2 selected from the group consisting of SEQ ID NOs: 14 to 16 and L-CDR3 selected from the group consisting of SEQ ID NOs: 17 to 19. In the present invention the light chain variable region comprising SEQ ID NO: 12 as L-CDR1, SEQ ID NO: 16 as L-CDR2 and SEQ ID NO: 18 as L-CDR3.
- In one embodiment, the isolated anti-Globo H antibody is a monocloncal antibody. Monoclonal antibodies to Globo H can be made according to knowledge and skill in the art. For example, it can be made by injecting test subjects with Globo H conjugate of the invention and then isolating hybridomas expressing antibodies having the desired sequence or functional characteristics.
- DNA encoding the monoclonal antibodies is readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of the monoclonal antibodies). The hybridoma cells serve as a preferred source of such DNA. Once isolated, the DNA may be placed into expression vectors, which are then transfected into host cells such as E. coli cells, simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. Recombinant production of antibodies will be described in more detail below.
- In a further embodiment, antibodies or antibody fragments can be isolated from antibody phage libraries generated using the conventional techniques known in the art; for example, the isolation of murine and human antibodies, respectively, using phage libraries. Subsequent publications describe the production of high affinity (nM range) human antibodies by chain shuffling, as well as combinatorial infection and in vivo recombination as a strategy for constructing very large phage libraries. Thus, these techniques are viable alternatives to traditional monoclonal antibody hybridoma techniques for isolation of monoclonal antibodies.
- In one aspect, the disclosure provides an isolated anti-Globo H antibody, comprising (i) a heavy chain variable region comprising an amino acid sequence having at least 85% identical to any of the amino acid sequences of SEQ ID NOs: 140 to 163, and (ii) a light chain variable region comprising an amino acid sequence having at least 80% identical to any of the amino acid sequence of SEQ ID NO: 164 to 199. Preferably, the sequence identity as mentioned above is at least 90%, 91%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%.
- The present invention provides an isolated anti-Globo H antibody, comprising (i) a heavy chain variable region comprising an amino acid sequence having at least 85% identical to the amino acid sequences of SEQ ID NO: 147, and (ii) a light chain variable region comprising an amino acid sequence having at least 80% identical to the amino acid sequence of SEQ ID NO: 195. In a further embodiment, the present invention provides an isolated anti-Globo H antibody, comprising (i) a heavy chain variable region comprising an amino acid sequence consisting of SEQ ID NO: 147, and (ii) a light chain variable region comprising an amino acid sequence consisting of SEQ ID NO: 195 (MZ-2 antibody). The nucleotides encoding the heavy chian variable region having the amino acid sequence of SEQ ID NO: 147 are as follows: The nucleotides encoding the light chian variable region having the amino acid sequence of SEQ ID NO: 195 are as follows:
-
-
- In another embodimetn, the isolated anti-Globo H antibody of the presetn invention is a humanized or chimeric antibody or fragment thereof capable of specifically binding to Globo H.
- In a further aspect, the disclosure provides a humanized anti-Globo H antibody or an antigen-binding portion thereof, comprising (i) a heavy chain variable region comprising an amino acid sequence having at least 85% identical to any of the amino acid sequences of SEQ ID NOs: 20 to 43, and (ii) a light chain variable region comprising an amino acid sequence having at least 80% identical to any of the amino acid sequence of SEQ ID NO: 44 to 79 and 200 to 235. Preferably, the sequence identity as mentioned above is at least 90%, 91%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%.
- In another aspect, the disclosure provides a humanized anti-Globo H antibody or an antigen-binding portion thereof, comprising (i) a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 20 to 43, and (ii) a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 44 to 79 and 200 to 235. In another embodiment, the humanized anti-Globo H antibody or an antigen-binding portion thereof comprises a heavy chain variable region comprising an amino acid sequence consisting of SEQ ID NO: 27, and a light chain variable region comprising an amino acid sequence consisting of SEQ ID NO: 75 (hMZ-2Lw antibody). In the invention, the humanized anti-Globo H antibody or an antigen-binding portion thereof can comprise a heavy chain variable region comprising an amino acid sequence consisting of SEQ ID NO: 27, and a light chain variable region comprising an amino acid sequence consisting of SEQ ID NO: 231.
-
-
- In a further aspect, the disclosure provides a humanized anti-Globo H antibody or an antigen-binding portion thereof, comprising (i) a heavy chain variable region comprising an amino acid sequence having at least 85% identical to any of the amino acid sequences of SEQ ID NOs: 80 to 103, and (ii) a light chain variable region comprising an amino acid sequence having at least 80% identical to any of the amino acid sequence of SEQ ID NOs: 104 to 139. Preferably, the sequence identity as mentioned above is at least 90%, 91%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%.
- In another further aspect, the disclosure provides a humanized anti-Globo H antibody or an antigen-binding portion thereof, comprising (i) a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 80 to 103, and (ii) a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 104 to 139.
- In the invention, the humanized anti-Globo H antibody or an antigen-binding portion thereof can comprise a heavy chain variable region comprising an amino acid sequence consisting of SEQ ID NO: 90, and a light chain variable region comprising an amino acid sequence consisting of SEQ ID NO: 135 (MK1 antibody).
-
-
- A humanized antibody has one or more amino acid residues from a source that is non-human. The non-human amino acid residues are often referred to as "import" residues, and are typically taken from an "import" variable domain. Humanization can be performed generally following conventional method known in the art, by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Accordingly, such "humanized" antibodies are antibodies wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species. In practice, humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in non-human, for example, rodent antibodies.
- The choice of human variable domains, both light and heavy, to be used in making the humanized antibodies is very important to reduce antigenicity. The sequence of the variable domain of a rodent antibody is screened against the entire library of known human variable-domain sequences. The human sequence which is closest to that of the rodent is then accepted as the human framework (FR) for the humanized antibody. Another method uses a particular framework derived from the consensus sequence of all human antibodies of a particular subgroup of light or heavy chains. The same framework may be used for several different humanized antibodies.
- It is further important that antibodies be humanized with retention of high affinity for the antigen and other favorable biological properties. To achieve this goal, according to a preferred method, humanized antibodies are prepared by a process of analysis of the parental sequences and various conceptual humanized products using three-dimensional models of the parental and humanized sequences. Three-dimensional immunoglobulin models are commonly available and are familiar to those skilled in the art. Computer programs are available which illustrate and display probable three-dimensional conformational structures of selected candidate immunoglobulin sequences. Inspection of these displays permits analysis of the likely role of the residues in the functioning of the candidate immunoglobulin sequence, i.e., the analysis of residues that influence the ability of the candidate immunoglobulin to bind its antigen. In this way, FR residues can be selected and combined from the recipient and import sequences so that the desired antibody characteristic, such as increased affinity for the target antigen(s), is achieved. In general, the CDR residues are directly and most substantially involved in influencing antigen binding.
- In one aspect, the disclosure provides a chimeric anti-Globo H antibody or an antigen-binding portion thereof, comprising (i) a heavy chain variable region comprising an amino acid sequence having at least 85% identical to any of the amino acid sequences of SEQ ID NOs: 140-163 wherein the last third sequence V of the amino acid sequences is changed as I, and (ii) a light chain variable region comprising an amino acid sequence having at least 80% identical to any of the amino acid sequence of SEQ ID NO:164-199. Preferably, the sequence identity as mentioned above is at least 90%, 91%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%.
- In one embodiment, the present invention provides a chimeric anti-Globo H antibody, comprising (i) a heavy chain variable region comprising an amino acid sequence having at least 85% identical to the amino acid sequences of SEQ ID NO: 147 wherein the last third sequence V of the amino acid sequence is changed as I, and (ii) a light chain variable region comprising an amino acid sequence having at least 85% identical to the amino acid sequence of SEQ ID NO: 195. In a further embodiment, the present invention provides an isolated anti-Globo H antibody (cMZ-2), comprising (i) a heavy chain variable region comprising an amino acid sequence consisting of SEQ ID NO: 147 wherein the last third sequence V of the amino acid sequences is changed as I, and (ii) a light chain variable region comprising an amino acid sequence consisting of SEQ ID NO: 195.
- The production of the chimeric antibody can be produced according to conventional methods known in the art. Methods for producing chimeric antibodies are known in the art. See e.g., Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214 (1986); Gillies et al., (1989) J. Immunol. Methods 125:191-202;
U.S. Pat. Nos. 5,807,715 ;4,816,567 ; and4,816,397 . In addition, techniques developed for the production of "chimeric antibodies" (Morrison et al., 1984, Proc. Natl. Acad. Sci. 81:851-855; Neuberger et al., 1984, Nature 312:604-608; Takeda et al., 1985, Nature 314:452-454) by splicing genes from a mouse antibody molecule of appropriate antigen specificity together with genes from a human antibody molecule of appropriate biological activity can be used. In some embodiments, the constant domains of the light and heavy chains of, for example, a mouse monoclonal antibody can be substituted 1) for those regions of, for example, a human antibody to generate a chimeric antibody or 2) for a non-immunoglobulin polypeptide to generate a fusion antibody. In other embodiments, the constant regions are truncated or removed to generate the desired antibody fragment of a monoclonal antibody. Furthermore, site-directed or high-density mutagenesis of the variable region can be used to optimize specificity, affinity, etc. of a monoclonal antibody. - In another aspect, the present invention provides a pharmaceutical composition comprising an anti-Globo H antibody or an antigen-binding portion thereof. The present antibody can also be formulated into a pharmaceutical composition. In addition to the antibody or an antigen-binding portion thereof, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.
- Administration of the anti-Globo H antibody or an antigen-binding portion thereof described herein, can include formulation into pharmaceutical compositions or pharmaceutical formulations for parenteral administration, e.g., intravenous; mucosal, e.g., intranasal; ocular, or other mode of administration. In some embodiments, the anti-Globo H antibody or an antigen-binding portion thereof described herein can be administered along with any pharmaceutically acceptable carrier compound, material, or composition which results in an effective treatment in the subject. Thus, a pharmaceutical formulation/composition for use in the methods described herein can contain an anti-Globo H antibody or an antigen-binding portion thereof as described herein in combination with one or more pharmaceutically acceptable carriers.
- The phrase "pharmaceutically acceptable" refers to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio. The phrase "pharmaceutically acceptable carrier" as used herein means a pharmaceutically acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent, media, encapsulating material, manufacturing aid (e.g., lubricant, talc magnesium, calcium or zinc stearate, or steric acid), or solvent encapsulating material, involved in maintaining the stability, solubility, or activity of, an anti-Globo H antibody or an antigen-binding portion thereof as described herein. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. The terms "excipient", "carrier", "pharmaceutically acceptable carrier", or the like are used interchangeably herein.
- The anti-Globo H antibody or an antigen-binding portion thereof as described herein can be specially formulated for administration of the compound to a subject in solid, liquid or gel form, including those adapted for the following: (1) parenteral administration, for example, by subcutaneous, intramuscular, intravenous or epidural injection as, for example, a sterile solution or suspension, or sustained-release formulation; (2) topical application, for example, as a cream, ointment, or a controlled-release patch or spray applied to the skin; (3) intravaginally or intrarectally, for example, as a pessary, cream or foam; (4) ocularly; (5) transdermally; (6) transmucosally; or (79) nasally. Additionally, a anti-Globo H antibody or an antigen-binding portion thereof as described herein can be implanted into a patient or injected using a drug delivery system.
- According to various working examples presented below, adult C57BL/6 mice (weight 20-25 grams) administered with the present antibody twice a week achieved reduced tumor size on 3 to 21 days after inoculation. Hence, in certain embodiments of the present disclosure, the therapeutically effective amount of the antibody for mice could be expressed as 0.8-100 mg/kg body weight. HED of the above-mentioned murine effective amount is about 0.65-81.5 mg/kg body weight. According to various embodiments of the present disclosure, when the subject is human, the therapeutically effective amount of the antibody can be at least 1 mg/kg. Depending on the type and severity of the disease, about 1 mg/kg to 150 mg/kg (e.g., 0.1-20 mg/kg) of an anti-Globo H antibody or an antigen-binding portion thereof as described herein is an initial candidate dosage for administration to a subject, whether, for example, by one or more separate administrations, or by continuous infusion. A typical daily dosage might range from about 1 mg/kg to about 100 mg/kg or more, depending on the factors mentioned above. Typical dosages include, for example, 5 mg/kg, 10 mg/kg, 20 mg/kg, and 30 mg/kg. For repeated administrations over several days or longer, depending on the condition, the treatment is sustained until, for example, the cancer is treated, as measured by the methods described above or known in the art.
- In another aspect, the disclosure provides a method of treating and/or preventing a cancer, comprising administering to a subject in need thereof a therapeutically effective amount of an anti-Globo H antibody or an antigen-binding portion thereof as described herein or a pharmaceutical composition comprising an anti-Globo H antibody or an antigen-binding portion thereof as described herein.
- The administration of the antibody or the pharmaceutical composition comprising the same to a subject confers passive protection to the subject and thereby provides the intended therapeutic effect to a cancer, such as tumor-associated carbohydrate-expressing cancer; preferably, breast cancer, ovarian cancer, pancreatic cancer, prostate cancer, colorectal cancer and lung cancer.
- In some embodiments, the anti-Globo H antibody or an antigen-binding portion thereof as described herein or a pharmaceutical composition comprising an anti-Globo H antibody or an antigen-binding portion thereof as described herein is administered to a subject having a cancer to be inhibited by any mode of administration that delivers the agent systemically or to a desired surface or target, and can include, but is not limited to, injection, infusion, instillation, and inhalation administration. To the extent that anti-Globo H antibody or an antigen-binding portion thereof as described herein or a pharmaceutical composition comprising an anti-Globo H antibody or an antigen-binding portion thereof as described herein can be protected from inactivation in the gut, oral administration forms are also contemplated. "Injection" includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intraventricular, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, sub capsular, subarachnoid, intraspinal, intracerebro spinal, and intrasternal injection and infusion. In preferred embodiments, the anti-Globo H antibody or an antigen-binding portion thereof as described herein or a pharmaceutical composition comprising an anti-Globo H antibody or an antigen-binding portion thereof as described herein for use in the methods described herein are administered by intravenous infusion or injection.
- The phrases "parenteral administration" and "administered parenterally" as used herein, refer to modes of administration other than enteral and topical administration, usually by injection. The phrases "systemic administration," "administered systemically", "peripheral administration" and "administered peripherally" as used herein refer to the administration of the bispecific or multispecific polypeptide agent other than directly into a target site, tissue, or organ, such as a tumor site, such that it enters the subject's circulatory system and, thus, is subject to metabolism and other like processes.
- The methods provided herein for inhibiting or treating cancer in subject having or at risk for cancer by administering to the subject a therapuetically effective amount of an anti-Globo H antibody or an antigen-binding portion thereof as described herein or a pharmaceutical composition comprising an anti-Globo H antibody or an antigen-binding portion thereof as described herein, can, in some embodiments, further comprise administration one or more additional treatments such as angiogenic inhibitors, chemotherapy, radiation, surgery, or other treatments known to those of skill in the art to prevent and/or treat cancer.
- The following Examples are provided to elucidate certain aspects of the present invention and to aid those of skilled in the art in practicing this invention. These Examples are in no way to be considered to limit the scope of the invention in any manner. Without further elaboration, it is believed that one skilled in the art can, based on the description herein, utilize the present invention to its fullest extent.
- Adult female C57BL/6 mice (n=3 each group; 5 weeks old; average weight 16-20 grams; purchased from Biolasco, Taiwan) were immunized by subcutaneous injection with 6 µg of Globo H-PADRE glycopeptide wherein PARDE represents a polypeptide of AKXVAAWTLKAAA (SEQ ID NO:238), and 50 µl of complete Freund's adjuvant (CFA; from Sigma). Four immunizations were given at a 2-week interval. Three days after the fourth immunization, immunized splenocytes were harvest and washed with serum-free medium. Subsequently, 1x108 of single cell suspended splenocytes were mixed with 2x107 of FO cells, and cell fusion was performed in 1 ml of 50% PEG 1500 solution (Roche) at 37°C followed by drop-wise addition of 13 ml of warmed RPMI medium (Gibco). Fused cells were centrifuged and washed twice with complete medium. Cells were then resuspended in complete medium with 1x BM-Conditioned H1 Hybridoma cloning supplement (Roche) and seeded into 96-well plates. For target specific B cell-myeloma cells fusion, immunized splenocytes were incubated with Globo H-biotin (10 µg/ml) in serum-free RPMI medium for 3 hours at 4°C. After being washed three times with the same medium, Globo H-binotin-bearing cells were resuspended at a concentration of 1x108 cells/ml and incubated with streptavidin (50 µg/ml) for 30 minutes at 4°C. Meanwhile, FO cells were incubated with 50 µg/ml of NHS-biotin for 1 hour at 4°C. Both treated cells were then washed three times with serum-free RPMI medium. Then, 1x108 splenocytes and 2x107 FO cells were mixed together, and chemical cell fusion was performed as describe above. After cell fusion, cells were cultured in RPMI 1640 medium containing 1xHAT medium (Gibco) for further selection.
- Mmonoclonal antibody-producing hybridoma cell lines were screened through limited dilution by ELISA assay on plate coated with Globo H-biotin antigen. Five clones (named MZ-1 to MZ-5, respectively) capable of secreting high-titers of anti-Globo H IgG or IgM antibodies were obtained.
- Supernatants from these hybridoma lines were also subjected to cell binding assay. Briefly, 100 µl of the supernatant from the hybridoma culture was incubated with 2x105 of MCF-7 cells and then analyzed by flow cytometry with appropriate fluorescent secondary antibody mentioned below. The cells were washed once with 2 ml of 1x PBS. After centrifugation, the wash buffer was discarded and cells were resuspended in 100 µl of 1:100 diluted PE anti-mouse IgG-Fc (Jackson immunoresearch) or 100 µl of 1:100 diluted PE anti-mouse IgM (eBioscience) and incubated again at room temperature for 20 minutes. The cells were washed with PBS and resuspended in 200 µl of 1x PBS after centrifugation. The binding of antibodies with cells were detected by flow cytometry. The results provided in
Figures 1A to E reveal that the monoclonal antibody produced by MZ-2 hybridoma (seeFig. 1C ) (hereinafter, the MZ-2 antibody) had good binding affinity to MCF-7 cells. For comparison purpose, a commercially available anti-Globo H IgG3 antibody (see Fig. E), VK9 antibody (see Fig. B) (eBioscience), was also analyzed. - Variable regions of heavy and light chains of MZ-2 antibody were first cloned to human IgG1 and kappa chain conserved region expression vectors to form mouse-human chimeric MZ-2 (cMZ-2). The cMZ-2 antibody has been gone through humanization by CDR-grafting based on structure analysis and sequence homology. The humanized MZ-2 antibody (hMZ-2) could be readily expressed as a recombinant IgG in mammalian cells and retains the antigen-binding affinity and specificity of the parent mouse antibody. We further improved its binding affinity with selective mutations of CDR and framework sequences that flank the CDR. The humanized construct was further transfected into FO cells by electroporation and selected by associated antibiotics to generate stable expression clones. Antibodies produced from the FO cells were checked by flow cytometry analysis. To obtain large-scale hMZ-2 antibodies for anti-tumor assay in vivo, 1x06 of hMZ-2 expression FO cells were first i.p. injected into NOD/SCID mice. Ascites from these mice were harvest after 2 weeks and passed through protein G agarose column to purify the generated antibody. The thus-obtained hMZ-2 antibodies were sequenced. The hMZ-2 antibody, hMz-2Lw (variable region of heavy chain: SEQ ID No. 27; variable region of light chain: SEQ ID No. 75 and MK1 (variable region of heavy chain: SEQ ID No. 90; variable region of light chain: SEQ ID No. 135), were used in the following examples.
- Primary human ovarian cancer tissues were obtained under the approval of IRB and patient consent. Ovarian cancer tissues were digested by MASC Tumor Dissociation kit (MASC, 130-095-929). The single cell suspension was stained with MZ-2 monoclonal antibody (10 µg/ml ; 100µl) for 30 minutes at 4°C., and stained with secondary antibody anti-mouse IgG1 PE(1:50; eBioscience, 2-405-82), then fixed with 4% paraformaldehyde for 1 min at RT. The cell were then stained with FITC-conjugated mouse anti-human EpCAM (1:50; biolegend, 324204), and mouse anti-human SSEA4 (1:50;biolegend, 330408) for 30 min at 4°C. Flow cytometric analysis was conducted on a Becton Dickinson FACScan (BD FACSCalibur).
Figures 2 demonstrate that the present MZ-2 monoclonal antibody exhibited good binding to primary ovarian cancer cells. Most epithelial primary cancer cells were stained with either MZ-2 or SSEA4 antibody showing by representative flow cytometry. EpCAM staining here represents a marker of epithelial cell. - Biotinylated-carbohydrates were conjugated on BD Cytometric Beads via Avidin by Functional Bead Conjugation Buffer Set (BD). First, 75 µL of the functional beads were sonicated and incubated with 1.9 µL of 1M DTT at room temperature for 1 hr. At the same time, 20 uL of each biotin-carbohydrate (0.2mg/mL) was mixed with 90 µg of maleimide activated neutrAvidin (1mg/mL in coupling buffer; Pierce) and incubated at room temperature for 1 hr. The beads were washed 3 times with 1 mL of coupling buffer and resuspended in 20 µL of coupling buffer. The carbohydrate were then mixed with designed beads and incubated with further one hour. 2 µL of N-Ethylmaleimide (2mg/mL on DMSO, Pierce) was then added into the conjugated beads and incubated for further 15 min. After 3 time wash, the beads were suspended in 500 µL of storage buffer and ready for use.
- For detecting the specificity and relative titer of anti-Globo H antibody, each set of carbohydrate-conjugated beads were mixed and diluted to 1:50 of each. 50 µL of bead mixture was then transfer to V buttom 96-well plate, and mixed with 50 µL of 1:1000 diluted serum or 1 µg/mL of MZ-2 antibody. After incubation for 30 min, the beads were washed with 150 µL of wash buffer and further stained with 100 µL of PE-conjugated 2Ab (Jackson Immunoresearch). The binding of anti-Globo H antibody were detected by FACS.
Figure 3 show the specificity of MZ-2 antibody is indicated by the fact that MZ-2 and chimeric MZ-2 antibodies only bind to Globo H-conjugated beads, but not SSEA3- or SSEA4-conjugated beads. - The 3-D structure of variable regions in original and humanized MZ-2 clones were simulated by Prediction of Immunoglobulin Structure online program.
Figures 4A and B show the simulation of protein folding of mouse MZ-2 monoclonal antibody (Fig. 4A ) and humanized MZ-2 monoclonal antibodies (Fig. 4B ). - The binding affinity of anti-Globo H antibody was detected by Biolayer interferometry using FortrBio OcTet system. Briefly, the sensors were first soaked in 20 µM of biotinylated Globo H to coat Globo H on their surface. The MZ-2 clone (mMZ-2), mouse-human chimerical MZ-2 clone (cMZ-2), and humanized MZ-2 clones (hMZ-2L, MK-1or hMZ-2Lw) were serially diluted into 1333, 444.4, 148.1, 49.4 and 16.5 nM, and incubated with Globo H coated sensors separately. 10mM of Glycine (pH 1.5) was used as Regeneration buffer.
Figures 5A and B show biacore full binding kinetic analysis of MZ-2 antibodies were carried out. Detailed binding kinetic parameters (association rate, ka, dissociation rate, kd, and affinity constant, KD) were determined by full kinetic analysis. Sensograms for each antibody are shown. The KD values of three humanized MZ-2 antibodies (hMZ-2L (seeFig. 5C ), MK-1 (seeFig. 5D ) and hMZ-2Lw (seeFig. 5E )) and chimeric MZ-2 (cMZ-2) antibody (seeFig. 5B ) are similar. - MCF-7, TOV21G Globo H(+), and HPAC cells were adjusted to 2 x 106 cells/ mL in RPMI 1640 medium and
aliquot 50 µL of diluted cells into flow tubes. The chimeric MZ-2 antibody was diluted to 2x designed concentration in RPMI 1640 medium andaliquot 50 µL to each flow tube with cancer cells. Human IgG (Fitzgerald, 31-AI06) was diluted into the same concentration as a control. After 15 min, 100 µL of normal human serum from healthy human donor was added into each tube and incubated at 37°C for 2hr. The cells were washed once with complete medium and resuspended in 200 µL of complete medium with 0.5 µg/mL propidium iodide. The percentage of dead cells was analyzed using FACS. - Results of complement-dependent cytotoxicity (CDC) assay, as reported in
Figure 6 , indicate that the human serum containing more than 1.6 µg/ml of hMZ-2Lw antibody elicited complement-dependent cytotoxicity in breast cancer, MCF-7 cells. The CDC increased in a dose-dependent manner. Similar trends were also observed in ovarian and pancreatic cancer cells in which hMZ-2Lw antibody in a concentration higher than about 10 and 20µg/ml resulted in a dose-dependent cytotoxicity in human ovarian cancer cell line TOV21 G (Figure 7 ), or the pancreatic cancer cell line, HPAC (seeFigure 8 ). - Briefly, 7.5 x 103 (100 uL) of each cells were pre-seeded into the designed wells of 96-well assay plate (Corning Cat.# 3917) and incubated overnight in a CO2 incubator at 37°C. The humanized anti-Globo H antibody clone hMZ-2Lw or MK1 was diluted into 3x highest concentration of assay and 4x serial dilution by 8 times. Noraml human IgG in the same concentration was used as control. ADCC assay was performed by ADCC Reporter Bioassay kit (Promega Cat.# G7010) at a E/T ratio of 10:1 and detected by chemoluminescent reader (EnSpire 2300, PerkinElmer). The folds of induced ADCC response were calculated as equation below:
-
Figures 9A and B andFigures. 10A and B respectively summarizes the antigen-dependent cell-mediated cytotoxicity (ADCC) activity of the present hMZ-2Lw and MK1 antibodies on MCF-7 cells (breast cancer cell line) and TOV21G cells (ovarian cancer cell line). In general, these results demonstrate that the present humanized MZ-2 antibody may elicit efficient and dose-dependent ADCC in MCF-7 and TOV21G cells. - For establishing an intra-peritoneal ovarian tumor model, 1x106 of TOV21G cells were intraperitoneally (i.p.) injected into 5-week-old female NU/NU mice (BioLASCO Taiwan). Two days later, mice were divided into 4 groups and administered with either 100µg (at a therapeutic dose of 5 mg/kg) of Human IgG, anti-GloboH antibodies hMZ-2Lw or MK1 twice a week through tail vein (i.v.) route. Untreated mice were set as control. To monitor the tumor growth, tumor bearing mice were i.p. injected 200µL of luciferin (3.9mg/ml) and the chemoluminance intensity of each mouse was detected by a non-invasive IVIS system (Xenogen) with fixed exposure condition in each different batch of experiment. Representative photograph in
Figure 11 illustrates administration of both hMZ-2Lw and MK1 antibodies significantly inhibit the tumor growth, while control IgG antibody did not substantially affect the tumor growth. However, the present hMZ-2 antibody significantly reduced the tumor size. By 24 days after treatment, tumor was nearly eliminated in mice given hMZ-2Lw antibody. - For establishing a subcutaneous breast tumor model, 17b-estradiol (Innovative Research of America, SE-121) was first subcutaneously (s.c.) implanted into NU/NU mice (BioLASCO Taiwan). Three days later, 3x106 MCF-7 cells mixed with matrigel were s.c. implanted (xenograft) into mice. Eighteen days after tumor challenge, mice were divided into 3 groups (n = 7), and treated by a therapeutic dose (5 mg/kg) of human IgG (100 µg/mouse) or 100 µg/mouse of hMZ-2Lw antibody i.v. (through tail vein) twice a week. Mice without treatment were set as control. Tumor size was measured weekly by calipers. The results of hMZ-2 antibody in breast cancer subcutaneous model MCF-7 cell are shown in
Figure 12 .Figures 13A and B shows the results of hMZ-2 antibody in pancreatic cancer subcutaneous model HPAC cell. - Briefly, 2 × 105 of Globo H-positive TOV21G cells were mixed with 5 µg of mouse IgG1 isotype or MZ-2 antibody (hMZ-2Lw) in 1 mL of culture medium in and incubated at 37°C for 15 min. These cells were then washed three times with 1x PBS and resuspended to 2 × 105 cells/mL in culture medium. One hundred micro liters of cells were transferred into the inserts of transwell (Corning) and incubated in CO2 incubator for 24 hr. Cells without antibody treatment, or Globo H-negative TOV21G cells were used as controls. Those cells on the top side of transwell membrane were removed by cotton rod. Migrated cells through the membrane (bottom side) were fixed with 4% formaldehyde and stained with crystal violate. The numbers of migrated cells were counted by tissue scanner (TissueGnostics).
Figure 14 shows that MZ-2 antibody inhibits migration of Globo H-expressing TOV21G cells. - Briefly, 2 × 105 of Globo H-expressing TOV21G cells were mixed with 5 µg of mouse IgG1 isotype (eBioscience) or MZ-2 antibody (hMZ-2Lw) in 0.5 mL of culture medium and incubated at 37°C for 15 min. Those cells were then washed three times with 1x PBS, and resuspended to 4 × 105 cells/mL in culture medium. One hundred micro liters of cells were transferred into a well of wound healing culture-inserts (Ibid Cat# 80241) in a 24-well plate and incubated for 8 hours in CO2 incubator. Cells without antibody treatment, or Globo H-negative TOV21G cells were used as controls. The insert were then removed and the cells were kept cultured for another 18 hours. Cell images were took by CCD camera from 0 hr to 18 hr after insert removal. Note that the gap of cells treated by MZ-2 antibody is larger than that treated by IgG1 isotype control.
Figure 15 shows that MZ-2 antibody inhibits migration of Globo H-expressing TOV21G cells. - The antibodies of the invention having the heavy chain variable regions and the light chain variable regions as described herein were subjected to the binding affinity assay of Example 2, association and dissociation assay of Example 5, CDC assay of Example 6, ADCC assay of Example 7 and anti-tumor assay of Example 8 and show similar results to cMZ-2 antobody, hMZ-2Lw antibody and MK-1 antibody. For example, the KD value of the antibody having a heavy chain variable region of SEQ ID NO: 27, and a light chain variable region of SEQ ID NO: 231 is in the range of
1x 10-7 to1x 10-10 nM. -
- <110> MACKAY MEMORIAL HOSPITAL
- <120> ANTIBODIES AGAINST IMMUNOGENIC GLYCOPEPTIDES, COMPOSITION COMPRISING THE SAME AND USE THEREOF
- <130> M27480/PC0054
- <150>
US 61/955,216
<151> 2014-03-19 - <160> 238
- <170> PatentIn version 3.5
- <210> 1
<211> 12
<212> PRT
<213> Artificial Sequence - <220>
<223> heavy chain complementarity determining region 1 (H-CDR1) - <400> 1
- <210> 2
<211> 12
<212> PRT
<213> Artificial Sequence - <220>
<223> heavy chain complementarity determining region 1 (H-CDR1) - <400> 2
- <210> 3
<211> 12
<212> PRT
<213> Artificial Sequence - <220>
<223> heavy chain complementarity determining region 1 (H-CDR1) - <400> 3
- <210> 4
<211> 12
<212> PRT
<213> Artificial Sequence - <220>
<223> heavy chain complementarity determining region 1 (H-CDR1) - <400> 4
- <210> 5
<211> 13
<212> PRT
<213> Artificial Sequence - <220>
<223> heavy chain CDR2 (H-CDR2) - <400> 5
- <210> 6
<211> 13
<212> PRT
<213> Artificial Sequence - <220>
<223> heavy chain CDR2 (H-CDR2) - <400> 6
- <210> 7
<211> 13
<212> PRT
<213> Artificial Sequence - <220>
<223> heavy chain CDR3 (H-CDR3) - <400> 7
- <210> 8
<211> 13
<212> PRT
<213> Artificial Sequence - <220>
<223> heavy chain CDR3 (H-CDR3) - <400> 8
- <210> 9
<211> 13
<212> PRT
<213> Artificial Sequence - <220>
<223> heavy chain CDR3 (H-CDR3) - <400> 9
- <210> 10
<211> 10
<212> PRT
<213> Artificial Sequence - <220>
<223> light chain CDR1 (L-CDR1) - <400> 10
- <210> 11
<211> 10
<212> PRT
<213> Artificial Sequence - <220>
<223> light chain CDR1 (L-CDR1) - <400> 11
- <210> 12
<211> 10
<212> PRT
<213> Artificial Sequence - <220>
<223> light chain CDR1 (L-CDR1) - <400> 12
- <210> 13
<211> 10
<212> PRT
<213> Artificial Sequence - <220>
<223> light chain CDR1 (L-CDR1) - <400> 13
- <210> 14
<211> 7
<212> PRT
<213> Artificial Sequence - <220>
<223> light chain CDR2 (L-CDR2) - <400> 14
- <210> 15
<211> 7
<212> PRT
<213> Artificial Sequence - <220>
<223> light chain CDR2 (L-CDR2) - <400> 15
- <210> 16
<211> 7
<212> PRT
<213> Artificial Sequence - <220>
<223> light chain CDR2 (L-CDR2) - <400> 16
- <210> 17
<211> 9
<212> PRT
<213> Artificial Sequence - <220>
<223> light chain CDR3 (L-CDR3) - <400> 17
- <210> 18
<211> 9
<212> PRT
<213> Artificial Sequence - <220>
<223> light chain CDR3 (L-CDR3) - <400> 18
- <210> 19
<211> 9
<212> PRT
<213> Artificial Sequence - <220>
<223> light chain CDR3 (L-CDR3) - <400> 19
- <210> 20
<211> 123
<212> PRT
<213> Artificial Sequence - <220>
<223> Heavy chain variable region of hMZ-2 series - <400> 20
- <210> 21
<211> 123
<212> PRT
<213> Artificial Sequence - <220>
<223> Heavy chain variable region of hMZ-2 series - <400> 21
- <210> 22
<211> 123
<212> PRT
<213> Artificial Sequence - <220>
<223> Heavy chain variable region of hMZ-2 series - <400> 22
- <210> 23
<211> 123
<212> PRT
<213> Artificial Sequence - <220>
<223> Heavy chain variable region of hMZ-2 series - <400> 23
- <210> 24
<211> 123
<212> PRT
<213> Artificial Sequence - <220>
<223> Heavy chain variable region of hMZ-2 series - <400> 24
- <210> 25
<211> 123
<212> PRT
<213> Artificial Sequence - <220>
<223> Heavy chain variable region of hMZ-2 series - <400> 25
- <210> 26
<211> 123
<212> PRT
<213> Artificial Sequence - <220>
<223> Heavy chain variable region of hMZ-2 series - <400> 26
- <210> 27
<211> 123
<212> PRT
<213> Artificial Sequence - <220>
<223> Heavy chain variable region of hMZ-2 series - <400> 27
- <210> 28
<211> 123
<212> PRT
<213> Artificial Sequence - <220>
<223> Heavy chain variable region of hMZ-2 series - <400> 28
- <210> 29
<211> 123
<212> PRT
<213> Artificial Sequence - <220>
<223> Heavy chain variable region of hMZ-2 series - <400> 29
- <210> 30
<211> 123
<212> PRT
<213> Artificial Sequence - <220>
<223> Heavy chain variable region of hMZ-2 series - <400> 30
- <210> 31
<211> 123
<212> PRT
<213> Artificial Sequence - <220>
<223> Heavy chain variable region of hMZ-2 series - <400> 31
- <210> 32
<211> 123
<212> PRT
<213> Artificial Sequence - <220>
<223> Heavy chain variable region of hMZ-2 series - <400> 32
- <210> 33
<211> 123
<212> PRT
<213> Artificial Sequence - <220>
<223> Heavy chain variable region of hMZ-2 series - <400> 33
- <210> 34
<211> 123
<212> PRT
<213> Artificial Sequence - <220>
<223> Heavy chain variable region of hMZ-2 series - <400> 34
- <210> 35
<211> 123
<212> PRT
<213> Artificial Sequence - <220>
<223> Heavy chain variable region of hMZ-2 series - <400> 35
- <210> 36
<211> 123
<212> PRT
<213> Artificial Sequence - <220>
<223> Heavy chain variable region of hMZ-2 series - <400> 36
- <210> 37
<211> 123
<212> PRT
<213> Artificial Sequence - <220>
<223> Heavy chain variable region of hMZ-2 series - <400> 37
- <210> 38
<211> 123
<212> PRT
<213> Artificial Sequence - <220>
<223> Heavy chain variable region of hMZ-2 series - <400> 38
- <210> 39
<211> 123
<212> PRT
<213> Artificial Sequence - <220>
<223> Heavy chain variable region of hMZ-2 series - <400> 39
- <210> 40
<211> 123
<212> PRT
<213> Artificial Sequence - <220>
<223> Heavy chain variable region of hMZ-2 series - <400> 40
- <210> 41
<211> 123
<212> PRT
<213> Artificial Sequence - <220>
<223> Heavy chain variable region of hMZ-2 series - <400> 41
- <210> 42
<211> 123
<212> PRT
<213> Artificial Sequence - <220>
<223> Heavy chain variable region of hMZ-2 series - <400> 42
- <210> 43
<211> 123
<212> PRT
<213> Artificial Sequence - <220>
<223> Heavy chain variable region of hMZ-2 series - <400> 43
- <210> 44
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of hMZ-2 series - <400> 44
- <210> 45
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of hMZ-2 series - <400> 45
- <210> 46
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of hMZ-2 series - <400> 46
- <210> 47
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of hMZ-2 series - <400> 47
- <210> 48
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of hMZ-2 series - <400> 48
- <210> 49
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of hMZ-2 series - <400> 49
- <210> 50
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of hMZ-2 series - <400> 50
- <210> 51
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of hMZ-2 series - <400> 51
- <210> 52
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of hMZ-2 series - <400> 52
- <210> 53
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of hMZ-2 series - <400> 53
- <210> 54
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of hMZ-2 series - <400> 54
- <210> 55
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of hMZ-2 series - <400> 55
- <210> 56
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of hMZ-2 series - <400> 56
- <210> 57
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of hMZ-2 series - <400> 57
- <210> 58
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of hMZ-2 series - <400> 58
- <210> 59
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of hMZ-2 series - <400> 59
- <210> 60
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of hMZ-2 series - <400> 60
- <210> 61
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of hMZ-2 series - <400> 61
- <210> 62
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of hMZ-2 series - <400> 62
- <210> 63
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of hMZ-2 series - <400> 63
- <210> 64
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of hMZ-2 series - <400> 64
- <210> 65
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of hMZ-2 series - <400> 65
- <210> 66
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of hMZ-2 series - <400> 66
- <210> 67
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of hMZ-2 series - <400> 67
- <210> 68
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of hMZ-2 series - <400> 68
- <210> 69
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of hMZ-2 series - <400> 69
- <210> 70
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of hMZ-2 series - <400> 70
- <210> 71
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of hMZ-2 series - <400> 71
- <210> 72
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of hMZ-2 series - <400> 72
- <210> 73
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of hMZ-2 series - <400> 73
- <210> 74
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of hMZ-2 series - <400> 74
- <210> 75
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of hMZ-2 series - <400> 75
- <210> 76
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of hMZ-2 series - <400> 76
- <210> 77
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of hMZ-2 series - <400> 77
- <210> 78
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of hMZ-2 series - <400> 78
- <210> 79
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of hMZ-2 series - <400> 79
- <210> 80
<211> 123
<212> PRT
<213> Artificial Sequence - <220>
<223> Heavy chain variable region of MK1 series - <400> 80
- <210> 81
<211> 123
<212> PRT
<213> Artificial Sequence - <220>
<223> Heavy chain variable region of MK1 series - <400> 81
- <210> 82
<211> 123
<212> PRT
<213> Artificial Sequence - <220>
<223> Heavy chain variable region of MK1 series - <400> 82
- <210> 83
<211> 123
<212> PRT
<213> Artificial Sequence - <220>
<223> Heavy chain variable region of MK1 series - <400> 83
- <210> 84
<211> 123
<212> PRT
<213> Artificial Sequence - <220>
<223> Heavy chain variable region of MK1 series - <400> 84
- <210> 85
<211> 123
<212> PRT
<213> Artificial Sequence - <220>
<223> Heavy chain variable region of MK1 series - <400> 85
- <210> 86
<211> 123
<212> PRT
<213> Artificial Sequence - <220>
<223> Heavy chain variable region of MK1 series - <400> 86
- <210> 87
<211> 123
<212> PRT
<213> Artificial Sequence - <220>
<223> Heavy chain variable region of MK1 series - <400> 87
- <210> 88
<211> 123
<212> PRT
<213> Artificial Sequence - <220>
<223> Heavy chain variable region of MK1 series - <400> 88
- <210> 89
<211> 123
<212> PRT
<213> Artificial Sequence - <220>
<223> Heavy chain variable region of MK1 series - <400> 89
- <210> 90
<211> 123
<212> PRT
<213> Artificial Sequence - <220>
<223> Heavy chain variable region of MK1 series - <400> 90
- <210> 91
<211> 123
<212> PRT
<213> Artificial Sequence - <220>
<223> Heavy chain variable region of MK1 series - <400> 91
- <210> 92
<211> 123
<212> PRT
<213> Artificial Sequence - <220>
<223> Heavy chain variable region of MK1 series - <400> 92
- <210> 93
<211> 123
<212> PRT
<213> Artificial Sequence - <220>
<223> Heavy chain variable region of MK1 series - <400> 93
- <210> 94
<211> 123
<212> PRT
<213> Artificial Sequence - <220>
<223> Heavy chain variable region of MK1 series - <400> 94
- <210> 95
<211> 123
<212> PRT
<213> Artificial Sequence - <220>
<223> Heavy chain variable region of MK1 series - <400> 95
- <210> 96
<211> 123
<212> PRT
<213> Artificial Sequence - <220>
<223> Heavy chain variable region of MK1 series - <400> 96
- <210> 97
<211> 123
<212> PRT
<213> Artificial Sequence - <220>
<223> Heavy chain variable region of MK1 series - <400> 97
- <210> 98
<211> 123
<212> PRT
<213> Artificial Sequence - <220>
<223> Heavy chain variable region of MK1 series - <400> 98
- <210> 99
<211> 123
<212> PRT
<213> Artificial Sequence - <220>
<223> Heavy chain variable region of MK1 series - <400> 99
- <210> 100
<211> 123
<212> PRT
<213> Artificial Sequence - <220>
<223> Heavy chain variable region of MK1 series - <400> 100
- <210> 101
<211> 123
<212> PRT
<213> Artificial Sequence - <220>
<223> Heavy chain variable region of MK1 series - <400> 101
- <210> 102
<211> 123
<212> PRT
<213> Artificial Sequence - <220>
<223> Heavy chain variable region of MK1 series - <400> 102
- <210> 103
<211> 123
<212> PRT
<213> Artificial Sequence - <220>
<223> Heavy chain variable region of MK1 series - <400> 103
- <210> 104
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of MK1 series - <400> 104
- <210> 105
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of MK1 series - <400> 105
- <210> 106
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of MK1 series - <400> 106
- <210> 107
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of MK1 series - <400> 107
- <210> 108
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of MK1 series - <400> 108
- <210> 109
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of MK1 series - <400> 109
- <210> 110
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of MK1 series - <400> 110
- <210> 111
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of MK1 series - <400> 111
- <210> 112
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of MK1 series - <400> 112
- <210> 113
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of MK1 series - <400> 113
- <210> 114
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of MK1 series - <400> 114
- <210> 115
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of MK1 series - <400> 115
- <210> 116
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of MK1 series - <400> 116
- <210> 117
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of MK1 series - <400> 117
- <210> 118
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of MK1 series - <400> 118
- <210> 119
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of MK1 series - <400> 119
- <210> 120
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of MK1 series - <400> 120
- <210> 121
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of MK1 series - <400> 121
- <210> 122
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of MK1 series - <400> 122
- <210> 123
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of MK1 series - <400> 123
- <210> 124
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of MK1 series - <400> 124
- <210> 125
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of MK1 series - <400> 125
- <210> 126
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of MK1 series - <400> 126
- <210> 127
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of MK1 series - <400> 127
- <210> 128
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of MK1 series - <400> 128
- <210> 129
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of MK1 series - <400> 129
- <210> 130
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of MK1 series - <400> 130
- <210> 131
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of MK1 series - <400> 131
- <210> 132
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of MK1 series - <400> 132
- <210> 133
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of MK1 series - <400> 133
- <210> 134
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of MK1 series - <400> 134
- <210> 135
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of MK1 series - <400> 135
- <210> 136
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of MK1 series - <400> 136
- <210> 137
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of MK1 series - <400> 137
- <210> 138
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of MK1 series - <400> 138
- <210> 139
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of MK1 series - <400> 139
- <210> 140
<211> 123
<212> PRT
<213> Artificial Sequence - <220>
<223> Heavy chain variable region of MZ-2 series - <400> 140
- <210> 141
<211> 123
<212> PRT
<213> Artificial Sequence - <220>
<223> Heavy chain variable region of MZ-2 series - <400> 141
- <210> 142
<211> 123
<212> PRT
<213> Artificial Sequence - <220>
<223> Heavy chain variable region of MZ-2 series - <400> 142
- <210> 143
<211> 123
<212> PRT
<213> Artificial Sequence - <220>
<223> Heavy chain variable region of MZ-2 series - <400> 143
- <210> 144
<211> 123
<212> PRT
<213> Artificial Sequence - <220>
<223> Heavy chain variable region of MZ-2 series - <400> 144
- <210> 145
<211> 123
<212> PRT
<213> Artificial Sequence - <220>
<223> Heavy chain variable region of MZ-2 series - <400> 145
- <210> 146
<211> 123
<212> PRT
<213> Artificial Sequence - <220>
<223> Heavy chain variable region of MZ-2 series - <400> 146
- <210> 147
<211> 123
<212> PRT
<213> Artificial Sequence - <220>
<223> Heavy chain variable region of MZ-2 series - <400> 147
- <210> 148
<211> 123
<212> PRT
<213> Artificial Sequence - <220>
<223> Heavy chain variable region of MZ-2 series - <400> 148
- <210> 149
<211> 123
<212> PRT
<213> Artificial Sequence - <220>
<223> Heavy chain variable region of MZ-2 series - <400> 149
- <210> 150
<211> 123
<212> PRT
<213> Artificial Sequence - <220>
<223> Heavy chain variable region of MZ-2 series - <400> 150
- <210> 151
<211> 123
<212> PRT
<213> Artificial Sequence - <220>
<223> Heavy chain variable region of MZ-2 series - <400> 151
- <210> 152
<211> 123
<212> PRT
<213> Artificial Sequence - <220>
<223> Heavy chain variable region of MZ-2 series - <400> 152
- <210> 153
<211> 123
<212> PRT
<213> Artificial Sequence - <220>
<223> Heavy chain variable region of MZ-2 series - <400> 153
- <210> 154
<211> 123
<212> PRT
<213> Artificial Sequence - <220>
<223> Heavy chain variable region of MZ-2 series - <400> 154
- <210> 155
<211> 123
<212> PRT
<213> Artificial Sequence - <220>
<223> Heavy chain variable region of MZ-2 series - <400> 155
- <210> 156
<211> 123
<212> PRT
<213> Artificial Sequence - <220>
<223> Heavy chain variable region of MZ-2 series - <400> 156
- <210> 157
<211> 123
<212> PRT
<213> Artificial Sequence - <220>
<223> Heavy chain variable region of MZ-2 series - <400> 157
- <210> 158
<211> 123
<212> PRT
<213> Artificial Sequence - <220>
<223> Heavy chain variable region of MZ-2 series - <400> 158
- <210> 159
<211> 123
<212> PRT
<213> Artificial Sequence - <220>
<223> Heavy chain variable region of MZ-2 series - <400> 159
- <210> 160
<211> 123
<212> PRT
<213> Artificial Sequence - <220>
<223> Heavy chain variable region of MZ-2 series - <400> 160
- <210> 161
<211> 123
<212> PRT
<213> Artificial Sequence - <220>
<223> Heavy chain variable region of MZ-2 series - <400> 161
- <210> 162
<211> 123
<212> PRT
<213> Artificial Sequence - <220>
<223> Heavy chain variable region of MZ-2 series - <400> 162
- <210> 163
<211> 123
<212> PRT
<213> Artificial Sequence - <220>
<223> Heavy chain variable region of MZ-2 series - <400> 163
- <210> 164
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of MZ-2 series - <400> 164
- <210> 165
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of MZ-2 series - <400> 165
- <210> 166
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of MZ-2 series - <400> 166
- <210> 167
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of MZ-2 series - <400> 167
- <210> 168
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of MZ-2 series - <400> 168
- <210> 169
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of MZ-2 series - <400> 169
- <210> 170
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of MZ-2 series - <400> 170
- <210> 171
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of MZ-2 series - <400> 171
- <210> 172
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of MZ-2 series - <400> 172
- <210> 173
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of MZ-2 series - <400> 173
- <210> 174
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of MZ-2 series - <400> 174
- <210> 175
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of MZ-2 series - <400> 175
- <210> 176
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of MZ-2 series - <400> 176
- <210> 177
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of MZ-2 series - <400> 177
- <210> 178
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of MZ-2 series - <400> 178
- <210> 179
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of MZ-2 series - <400> 179
- <210> 180
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of MZ-2 series - <400> 180
- <210> 181
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of MZ-2 series - <400> 181
- <210> 182
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of MZ-2 series - <400> 182
- <210> 183
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of MZ-2 series - <400> 183
- <210> 184
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of MZ-2 series - <400> 184
- <210> 185
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of MZ-2 series - <400> 185
- <210> 186
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of MZ-2 series - <400> 186
- <210> 187
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of MZ-2 series - <400> 187
- <210> 188
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of MZ-2 series - <400> 188
- <210> 189
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of MZ-2 series - <400> 189
- <210> 190
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of MZ-2 series - <400> 190
- <210> 191
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of MZ-2 series - <400> 191
- <210> 192
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of MZ-2 series - <400> 192
- <210> 193
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of MZ-2 series - <400> 193
- <210> 194
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of MZ-2 series - <400> 194
- <210> 195
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of MZ-2 series - <400> 195
- <210> 196
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of MZ-2 series - <400> 196
- <210> 197
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of MZ-2 series - <400> 197
- <210> 198
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of MZ-2 series - <400> 198
- <210> 199
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of MZ-2 series - <400> 199
- <210> 200
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of hMZ-2 series - <400> 200
- <210> 201
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of hMZ-2 series - <400> 201
- <210> 202
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of hMZ-2 series - <400> 202
- <210> 203
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of hMZ-2 series - <400> 203
- <210> 204
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of hMZ-2 series - <400> 204
- <210> 205
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of hMZ-2 series - <400> 205
- <210> 206
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of hMZ-2 series - <400> 206
- <210> 207
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of hMZ-2 series - <400> 207
- <210> 208
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of hMZ-2 series - <400> 208
- <210> 209
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of hMZ-2 series - <400> 209
- <210> 210
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of hMZ-2 series - <400> 210
- <210> 211
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of hMZ-2 series - <400> 211
- <210> 212
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of hMZ-2 series - <400> 212
- <210> 213
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of hMZ-2 series - <400> 213
- <210> 214
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of hMZ-2 series - <400> 214
- <210> 215
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of hMZ-2 series - <400> 215
- <210> 216
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of hMZ-2 series - <400> 216
- <210> 217
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of hMZ-2 series - <400> 217
- <210> 218
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of hMZ-2 series - <400> 218
- <210> 219
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of hMZ-2 series - <400> 219
- <210> 220
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of hMZ-2 series - <400> 220
- <210> 221
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of hMZ-2 series - <400> 221
- <210> 222
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of hMZ-2 series - <400> 222
- <210> 223
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of hMZ-2 series - <400> 223
- <210> 224
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of hMZ-2 series - <400> 224
- <210> 225
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of hMZ-2 series - <400> 225
- <210> 226
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of hMZ-2 series - <400> 226
- <210> 227
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of hMZ-2 series - <400> 227
- <210> 228
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of hMZ-2 series - <400> 228
- <210> 229
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of hMZ-2 series - <400> 229
- <210> 230
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of hMZ-2 series - <400> 230
- <210> 231
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of hMZ-2 series - <400> 231
- <210> 232
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of hMZ-2 series - <400> 232
- <210> 233
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of hMZ-2 series - <400> 233
- <210> 234
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of hMZ-2 series - <400> 234
- <210> 235
<211> 107
<212> PRT
<213> Artificial Sequence - <220>
<223> Light chain variable region of hMZ-2 series - <400> 235
- <210> 236
<211> 369
<212> DNA
<213> Artificial Sequence - <220>
<223> Nucleotides of MZ-2 heavy chain variable region - <400> 236
- <210> 237
<211> 321
<212> DNA
<213> Artificial Sequence - <220>
<223> Nucleotides of light chain variable region - <400> 237
- <210> 238
<211> 13
<212> PRT
<213> Artificial Sequence - <220>
<223> amino acid sequence - <220>
<221> misc-feature
<222> (3)..(3)
<223> Xaa can be any naturally occurring amino acid - <400> 238
Claims (12)
- An isolated anti-Globo H antibody or an antigen-binding portion thereof, comprising the following:(i) a heavy chain complementarity determining region 1 (H-CDR1) consisting of the amino acid residues of GFSLGTFDLGIG (SEQ ID NO: 3); a heavy chain CDR2 (H-CDR2) consisting of the amino acid residues of HIWWDDDKYYNPA (SEQ ID NO:5); and a heavy chain CDR3 (H-CDR3) consisting of the amino acid residues of LSGNYLTSFYCDY (SEQ ID NO: 8); and
a light chain CDR1 (L-CDR1) consisting of the amino acid residues of SARSSVSYMH (SEQ ID NO:12); a light chain CDR2 (L-CDR2) consisting of the amino acid residues of DTSKLAS (SEQ ID NO:16); and a light chain CDR3 (L-CDR3) consisting of the amino acid residues of QQWSSNPLT (SEQ ID NO: 18); or(ii) a heavy chain complementarity determining region 1 (H-CDR1) consisting of the amino acid residues of GFSLSTFDLGIG (SEQ ID NO: 4); a heavy chain CDR2 (H-CDR2) consisting of the amino acid residues of HIWWDDDKYYNPA (SEQ ID NO:5); and a heavy chain CDR3 (H-CDR3) consisting of the amino acid residues of LSGNYLTSFYCDY (SEQ ID NO: 8); and
a light chain CDR1 (L-CDR1) consisting of the amino acid residues of SARSSVSYMH (SEQ ID NO:12); a light chain CDR2 (L-CDR2) consisting of the amino acid residues of DTSKLAS (SEQ ID NO:16); and a light chain CDR3 (L-CDR3) consisting of the amino acid residues of QQWSSNPLT (SEQ ID NO: 18);
such that said antibody or antigen-binding portion thereof binds to Globo H. - The isolated anti-Globo H antibody or an antigen-binding portion thereof of Claim 1, comprising (i) a heavy chain variable region comprising an amino acid sequence having at least 85% identical to the amino acid sequences of SEQ ID NO: 147, and (ii) a light chain variable region comprising an amino acid sequence having at least 80% identical to the amino acid sequence of SEQ ID NO: 195.
- The isolated anti-Globo H antibody or an antigen-binding portion thereof of Claim 2, comprising (i) a heavy chain variable region comprising an amino acid sequence consisting of SEQ ID NO: 147, and (ii) a light chain variable region comprising an amino acid sequence consisting of SEQ ID NO: 195.
- The isolated anti-Globo H antibody or an antigen-binding portion thereof of Claim 1, which is humanized and comprises (i) a heavy chain variable region comprising an amino acid sequence having at least 85% identical to an amino acid sequence consisting of SEQ ID NO: 27, and a light chain variable region comprising an amino acid sequence having at least 80% identical to an amino acid sequence consisting of SEQ ID NO: 75; or (ii) a heavy chain variable region comprising an amino acid sequence having at least 85% identical to an amino acid sequence consisting of SEQ ID NO: 27, and a light chain variable region comprising an amino acid sequence having at least 80% identical to an amino acid sequence consisting of SEQ ID NO: 231.
- The isolated anti-Globo H antibody or an antigen-binding portion thereof of Claim 1, which is humanized and comprises a heavy chain variable region comprising an amino acid sequence having at least 85% identical to an amino acid sequence consisting of SEQ ID NO: 90, and a light chain variable region comprising an amino acid sequence having at least 80% identical to an amino acid sequence consisting of SEQ ID NO: 135.
- A pharmaceutical composition, comprising the isolated anti-Globo H antibody or an antigen-binding portion thereof of any of Claims 1 to 5 and a pharmaceutically acceptable carrier.
- The pharmaceutical composition of Claim 6, which further comprises an anti-tumor drug.
- The isolated anti-Globo H antibody or an antigen-binding portion thereof of any of Claims 1 to 5 for use in a method of treating and/or preventing a cancer.
- The isolated anti-Globo H antibody or an antigen-binding portion thereof for use according to Claim 8, wherein the cancer is a tumor-associated carbohydrate-expressing cancer.
- The isolated anti-Globo H antibody or an antigen-binding portion thereof for use according to Claim 8, wherein the cancer is a breast cancer, ovarian cancer, pancreatic cancer, prostate cancer, colorectal cancer or lung cancer.
- The isolated anti-Globo H antibody or an antigen-binding portion thereof for use according to Claim 8, wherein the cancer is a migration cancer.
- The isolated anti-Globo H antibody or an antigen-binding portion thereof for use according to Claim 8, wherein the treatment or prevention further comprises administration of one or more additional treatments selected from such as angiogenic inhibitors, chemotherapy, radiation or surgery.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461955216P | 2014-03-19 | 2014-03-19 | |
PCT/US2015/021413 WO2015143123A2 (en) | 2014-03-19 | 2015-03-19 | Antibodies against immunogenic glycopeptides, composition comprising the same and use thereof |
Publications (3)
Publication Number | Publication Date |
---|---|
EP3119432A2 EP3119432A2 (en) | 2017-01-25 |
EP3119432A4 EP3119432A4 (en) | 2017-09-13 |
EP3119432B1 true EP3119432B1 (en) | 2020-01-08 |
Family
ID=54145306
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP15765633.1A Active EP3119432B1 (en) | 2014-03-19 | 2015-03-19 | Antibodies against immunogenic glycopeptides, composition comprising the same and use thereof |
EP15764279.4A Withdrawn EP3119424A4 (en) | 2014-03-19 | 2015-03-19 | Immunogenic glycopeptides, composition comprising the glycopeptides and use thereof |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP15764279.4A Withdrawn EP3119424A4 (en) | 2014-03-19 | 2015-03-19 | Immunogenic glycopeptides, composition comprising the glycopeptides and use thereof |
Country Status (11)
Country | Link |
---|---|
US (4) | US20170143810A1 (en) |
EP (2) | EP3119432B1 (en) |
JP (1) | JP2017518958A (en) |
KR (1) | KR20170003912A (en) |
CN (2) | CN107073088A (en) |
AU (1) | AU2015231256A1 (en) |
CA (2) | CA2943334A1 (en) |
IL (1) | IL247659A0 (en) |
MX (1) | MX2016012124A (en) |
TW (2) | TWI681972B (en) |
WO (2) | WO2015143126A1 (en) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112016001775A2 (en) | 2013-07-31 | 2017-09-05 | Univ Arkansas | COMPOSITION, METHODS OF TREATMENT OF A HUMAN WHO HAS BEEN DIAGNOSED WITH CANCER, OF CANCER PREVENTION IN A HUMAN AT HIGH RISK OF RECEIVING CANCER, AND OF PRODUCING A COMPOSITION OF AN ISOLATED HUMAN ANTI-TUMOR NK CELL POPULATION AND A DENDRITIC CELL POPULATION HUMAN ANTITUMOR ISOLATED, HUMAN NK AND DENDRITIC CELLS ISOLATED, E, KIT |
AU2014391422A1 (en) | 2013-09-17 | 2015-12-17 | Obi Pharma, Inc. | Compositions of a carbohydrate vaccine for inducing immune responses and uses thereof in cancer treatment |
JP2017518958A (en) | 2014-03-19 | 2017-07-13 | マッカイ メディカル ファウンデイション ザ プレスビテリアン チャーチ イン タイワン マッカイ メモリアル ホスピタルMackay Medical Foundation The Presbyterian Church In Taiwan Mackay Memorial Hospital | Antibodies against immunogenic glycopeptides, compositions containing them, and uses thereof |
RU2016138744A (en) | 2014-04-10 | 2018-05-11 | Оби Фарма Инк. | ANTIBODIES, PHARMACEUTICAL COMPOSITIONS AND THEIR APPLICATIONS |
EP3344806A4 (en) | 2015-09-04 | 2019-03-20 | OBI Pharma, Inc. | Glycan arrays and method of use |
US20180264093A1 (en) * | 2015-09-18 | 2018-09-20 | Mackay Memorial Hospital Of Taiwan Presbyterian Church And Mackay Memorial Social Work Foundation | Immunogenic glycopeptide compounds, pharmaceutical compositions and uses thereof |
CN108472362B (en) | 2015-10-07 | 2022-03-29 | 台湾浩鼎生技股份有限公司 | Novel carbohydrate antibodies, pharmaceutical compositions and uses thereof |
US10980894B2 (en) | 2016-03-29 | 2021-04-20 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
KR20180121786A (en) | 2016-03-29 | 2018-11-08 | 오비아이 파머 인코퍼레이티드 | Antibodies, pharmaceutical compositions and methods |
TWI697333B (en) | 2016-04-22 | 2020-07-01 | 台灣浩鼎生技股份有限公司 | CANCER IMMUNOTHERAPY BY IMMUNE ACTIVATION OR IMMUNE MODULATION VIA Globo SERIES ANTIGENS |
KR20190067765A (en) | 2016-07-27 | 2019-06-17 | 오비아이 파머 인코퍼레이티드 | Immunogenicity / therapeutic glycan compositions and uses thereof |
KR102528998B1 (en) | 2016-07-29 | 2023-05-03 | 오비아이 파머 인코퍼레이티드 | Human Antibodies, Pharmaceutical Compositions and Methods |
WO2018054353A1 (en) * | 2016-09-23 | 2018-03-29 | Chang, Chih-Long | Anti-globo h antibodies |
CA3044274A1 (en) | 2016-11-21 | 2018-05-24 | Obi Pharma, Inc. | Conjugated biological molecules, pharmaceutical compositions and methods |
CA3064443A1 (en) * | 2017-05-24 | 2018-11-29 | Development Center For Biotechnology | Humanized antibodies against globo h and uses thereof in cancer treatments |
EP3638306A4 (en) * | 2017-06-15 | 2020-07-01 | Development Center for Biotechnology | Antibody-drug conjugates containing anti-globo h antibodies and uses thereof |
CA3068056A1 (en) * | 2017-06-22 | 2018-12-27 | Development Center For Biotechnology | Asymmetric heterodimeric fc-scfv fusion anti-globo h and anti-cd3 bispecifc antibody and uses thereof in cancer therapy |
WO2019217450A1 (en) | 2018-05-08 | 2019-11-14 | Rhode Island Hospital | Anti-chi3l1 antibodies for the detection and/or treatment of nonalcoholic fattly liver disease/nonalcoholic steatohepatitis and subsequent complications |
KR20210031651A (en) * | 2018-06-01 | 2021-03-22 | 오비아이 파머 인코퍼레이티드 | Combination therapy with anti-negative immune checkpoint antibodies and anti-GLOBO H or anti-SSEA-4 antibodies |
US11203645B2 (en) | 2018-06-27 | 2021-12-21 | Obi Pharma, Inc. | Glycosynthase variants for glycoprotein engineering and methods of use |
AU2019344524A1 (en) * | 2018-09-17 | 2021-03-25 | The Brigham And Women’S Hospital, Inc. | Anti-KLRG1 antibodies |
EP3799881A1 (en) * | 2019-10-04 | 2021-04-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Single domain antibodies specifically binding globo - series glycans |
CN110665001A (en) * | 2019-11-14 | 2020-01-10 | 上海农林职业技术学院 | Water-based composite adjuvant, application thereof and vaccine for cats |
CN112675298B (en) * | 2020-12-28 | 2024-05-03 | 中国医学科学院医学生物学研究所 | Immune adjuvant, vaccine containing same, preparation method and application |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050049197A1 (en) | 1993-09-14 | 2005-03-03 | Epimmune Inc. | Induction of immune response against desired determinants |
US6413935B1 (en) | 1993-09-14 | 2002-07-02 | Epimmune Inc. | Induction of immune response against desired determinants |
DE69435171D1 (en) | 1993-09-14 | 2009-01-08 | Pharmexa Inc | PAN DR BINDEPROTEINS FOR INCREASING THE IMMUNE RESPONSE |
US6544952B1 (en) | 1994-03-15 | 2003-04-08 | Sloan-Kettering Institute For Cancer Research | Synthesis of glycoconjugates of the globo-H epitope and uses thereof |
ES2177927T3 (en) * | 1996-01-24 | 2002-12-16 | Epimmune Inc | COMPOSITION TO CAUSE AN IMMUNOLOGICAL REACTION TO A NON-PROTEIN ANTIGEN DETERMINANT |
US6676946B2 (en) | 1997-03-27 | 2004-01-13 | Institut Pasteur | Multiple antigen glycopeptide carbohydrate vaccine comprising the same and use thereof |
US7018637B2 (en) | 1998-02-23 | 2006-03-28 | Aventis Pasteur, Inc | Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines |
GB0029360D0 (en) | 2000-12-01 | 2001-01-17 | Univ Nottingham | Humanised antibodies and uses thereof |
US20040142325A1 (en) * | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
WO2005094446A2 (en) * | 2004-03-23 | 2005-10-13 | Eli Lilly And Company | Anti-myostatin antibodies |
JP4702950B2 (en) * | 2005-03-28 | 2011-06-15 | キヤノン株式会社 | Electrophotographic photosensitive member, process cartridge and electrophotographic apparatus, and method for manufacturing electrophotographic photosensitive member |
US20070202578A1 (en) | 2005-08-26 | 2007-08-30 | Centre National De La Recherche Scientifique (Cnrs) | Production of globosides oligosaccharides using metabolically engineered microorganisms |
AU2006302494B2 (en) | 2005-10-06 | 2011-01-06 | Eli Lilly And Company | Anti-myostatin antibodies |
US8128926B2 (en) * | 2007-01-09 | 2012-03-06 | Biogen Idec Ma Inc. | Sp35 antibodies and uses thereof |
HUE031533T2 (en) | 2007-10-19 | 2017-07-28 | Seattle Genetics Inc | Cd19 binding agents and uses thereof |
DK2242773T3 (en) | 2008-02-11 | 2017-09-25 | Cure Tech Ltd | Monoclonal antibodies for tumor treatment |
WO2009137677A2 (en) | 2008-05-07 | 2009-11-12 | Innovative Biosensors, Inc. | Reagents, methods, and systems for detecting methicillin-resistant staphylococcus |
AU2009268937A1 (en) | 2008-06-16 | 2010-01-14 | Aj Park | Compositions for inducing immune responses specific to Globo H and SSEA3 and uses thereof in cancer treatment |
CN102066940B (en) * | 2008-06-16 | 2015-05-13 | 中央研究院 | Cancer diagnosis based on levels of antibodies against Globo H and its fragments |
AU2009268349C1 (en) | 2008-07-11 | 2015-01-22 | Sloan-Kettering Institute For Cancer Research | Glycopeptide constructs and uses thereof |
US7928077B2 (en) | 2008-07-11 | 2011-04-19 | Academia Sinica | Alpha-galactosyl ceramide analogs and their use as immunotherapies |
US9018358B2 (en) | 2009-04-30 | 2015-04-28 | University Of Rochester | DC-STAMP antibodies |
CN102215862B (en) * | 2009-06-16 | 2016-04-06 | 中央研究院 | GLOBO H and the relevant anti-cancer vaccine containing new glycolipids matter adjuvant |
TW201118166A (en) | 2009-09-24 | 2011-06-01 | Chugai Pharmaceutical Co Ltd | HLA class I-recognizing antibodies |
US10150808B2 (en) | 2009-09-24 | 2018-12-11 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant regions |
PT2547364T (en) * | 2010-03-15 | 2017-02-21 | Stichting Technische Wetenschappen | Peptides, conjugates and method for increasing immunogenicity of a vaccine |
AU2011235833A1 (en) | 2010-04-02 | 2012-10-25 | Kalobios Pharmaceuticals, Inc. | Generation of antibodies to an epitope of interest |
BR112012025730B1 (en) * | 2010-04-09 | 2020-12-08 | Aveo Pharmaceuticals, Inc | isolated antibody that binds to human erbb3, its uses, its production process and expression vector |
CN103209701B (en) * | 2010-06-11 | 2016-08-03 | 乔治亚大学研究基金公司 | Immunogenic vaccine |
WO2011156774A2 (en) | 2010-06-11 | 2011-12-15 | Sloan-Kettering Institute For Cancer Research | Multivalent glycopeptide constructs and uses thereof |
AR091116A1 (en) * | 2012-05-22 | 2015-01-14 | Bristol Myers Squibb Co | BISPECIFIC ANTIBODIES AND THEIR METHODS OF USE |
US9175076B2 (en) | 2012-12-21 | 2015-11-03 | Aveo Pharmaceuticals, Inc. | Anti-GDF15 antibodies |
RU2015131033A (en) | 2013-01-04 | 2017-02-09 | Оби Фарма, Инк. | HIGH-DENSITY VACCINES FOR CARBOHYDRATE ANTIGEN PLACEMENT AND THE NEW SAPONIN ADJUVANT |
CN104371019B (en) | 2013-08-13 | 2019-09-10 | 鸿运华宁(杭州)生物医药有限公司 | It is a kind of can with GLP-1R specifically bind antibody and its with the fused protein of GLP-1 |
AU2014391422A1 (en) | 2013-09-17 | 2015-12-17 | Obi Pharma, Inc. | Compositions of a carbohydrate vaccine for inducing immune responses and uses thereof in cancer treatment |
US20160264684A1 (en) | 2013-10-10 | 2016-09-15 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
JP2017518958A (en) | 2014-03-19 | 2017-07-13 | マッカイ メディカル ファウンデイション ザ プレスビテリアン チャーチ イン タイワン マッカイ メモリアル ホスピタルMackay Medical Foundation The Presbyterian Church In Taiwan Mackay Memorial Hospital | Antibodies against immunogenic glycopeptides, compositions containing them, and uses thereof |
RU2016138744A (en) | 2014-04-10 | 2018-05-11 | Оби Фарма Инк. | ANTIBODIES, PHARMACEUTICAL COMPOSITIONS AND THEIR APPLICATIONS |
-
2015
- 2015-03-19 JP JP2016556306A patent/JP2017518958A/en active Pending
- 2015-03-19 CN CN201580019341.6A patent/CN107073088A/en active Pending
- 2015-03-19 WO PCT/US2015/021421 patent/WO2015143126A1/en active Application Filing
- 2015-03-19 AU AU2015231256A patent/AU2015231256A1/en not_active Abandoned
- 2015-03-19 EP EP15765633.1A patent/EP3119432B1/en active Active
- 2015-03-19 US US15/126,990 patent/US20170143810A1/en not_active Abandoned
- 2015-03-19 TW TW104108906A patent/TWI681972B/en active
- 2015-03-19 MX MX2016012124A patent/MX2016012124A/en unknown
- 2015-03-19 CN CN201580014575.1A patent/CN106456766B/en not_active Expired - Fee Related
- 2015-03-19 KR KR1020167028309A patent/KR20170003912A/en unknown
- 2015-03-19 TW TW104108838A patent/TW201622743A/en unknown
- 2015-03-19 EP EP15764279.4A patent/EP3119424A4/en not_active Withdrawn
- 2015-03-19 WO PCT/US2015/021413 patent/WO2015143123A2/en active Application Filing
- 2015-03-19 CA CA2943334A patent/CA2943334A1/en not_active Abandoned
- 2015-03-19 US US15/126,945 patent/US9828436B2/en active Active
- 2015-03-19 CA CA2943333A patent/CA2943333A1/en not_active Abandoned
-
2016
- 2016-09-06 IL IL247659A patent/IL247659A0/en unknown
-
2017
- 2017-07-20 US US15/655,105 patent/US9951143B2/en active Active
-
2018
- 2018-03-15 US US15/922,810 patent/US20180371103A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
None * |
Also Published As
Publication number | Publication date |
---|---|
CA2943334A1 (en) | 2015-09-24 |
IL247659A0 (en) | 2016-11-30 |
US20170362337A1 (en) | 2017-12-21 |
EP3119424A4 (en) | 2017-09-13 |
WO2015143123A2 (en) | 2015-09-24 |
JP2017518958A (en) | 2017-07-13 |
US9828436B2 (en) | 2017-11-28 |
CN107073088A (en) | 2017-08-18 |
MX2016012124A (en) | 2017-04-06 |
CN106456766B (en) | 2020-03-10 |
EP3119432A2 (en) | 2017-01-25 |
EP3119424A1 (en) | 2017-01-25 |
CA2943333A1 (en) | 2015-09-24 |
WO2015143123A3 (en) | 2015-11-26 |
US20170107297A1 (en) | 2017-04-20 |
US20180371103A1 (en) | 2018-12-27 |
TW201623336A (en) | 2016-07-01 |
US20170143810A1 (en) | 2017-05-25 |
CN106456766A (en) | 2017-02-22 |
AU2015231256A1 (en) | 2016-09-22 |
US9951143B2 (en) | 2018-04-24 |
WO2015143126A1 (en) | 2015-09-24 |
TWI681972B (en) | 2020-01-11 |
KR20170003912A (en) | 2017-01-10 |
EP3119432A4 (en) | 2017-09-13 |
TW201622743A (en) | 2016-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9951143B2 (en) | Antibodies against immunogenic glycopeptides, compositions comprising the same and use thereof | |
AU2019274655B2 (en) | Antibodies specific for GUCY2c and uses thereof | |
JP6552621B2 (en) | Anti-PD-1 antibody and method of using the same | |
ES2780374T3 (en) | Anti-IL-7 Receptor Antagonist Antibodies and Procedures | |
KR102555955B1 (en) | Compositions and methods for treatment of diabetic macular edema | |
BR112020023746A2 (en) | antibody, pharmaceutical composition, method for treating cancer, isolated nucleic acid, vector, host cell, process for producing an antibody and diagnostic reagent | |
KR20190035863A (en) | Anti-Siglec-7 Antibody for Cancer Treatment | |
BRPI0815370B1 (en) | high-affinity human antibodies to human neural growth factor and its use, nucleic acid molecule, expression vector, method for producing a human anti-ngf antibody and pharmaceutical composition | |
BR112020009707A2 (en) | antibodies to a-synuclein and uses thereof | |
JP2017512790A5 (en) | ||
TWI793325B (en) | Antibodies specific for cd3 and uses thereof | |
CN113423736A (en) | Antibodies specific to MUC18 | |
KR20200104314A (en) | LAG-3 antibody pharmaceutical composition and use thereof | |
WO2019076277A1 (en) | Uses of anti-pd-1 antibody and anti-lag-3 antibody jointly in preparing medicament for treating tumor | |
TW202108623A (en) | Anti-trop-2 antibodies, antigen-binding fragments and medical use thereof | |
CN116323657B (en) | Bifunctional molecule for simultaneously targeting PD-L1 and TGF beta and medical application thereof | |
JP2022514786A (en) | MUC18-specific antibody | |
WO2022068894A1 (en) | Bifunctional molecule simultaneously targeting pd-l1 and vegf and medical use thereof | |
AU2009322587A1 (en) | Anti-ferroportin 1 monoclonal antibodies and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20161007 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20170814 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07K 16/00 20060101ALI20170808BHEP Ipc: A61K 39/00 20060101ALI20170808BHEP Ipc: A61K 39/40 20060101AFI20170808BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20180711 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Ref document number: 602015045189 Country of ref document: DE Free format text: PREVIOUS MAIN CLASS: A61K0039400000 Ipc: A61P0035000000 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 35/00 20060101AFI20190626BHEP Ipc: A61K 39/00 20060101ALI20190626BHEP Ipc: C07K 16/00 20060101ALI20190626BHEP Ipc: A61K 39/40 20060101ALI20190626BHEP |
|
INTG | Intention to grant announced |
Effective date: 20190729 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602015045189 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1221956 Country of ref document: AT Kind code of ref document: T Effective date: 20200215 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: FP |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20200312 Year of fee payment: 6 Ref country code: NL Payment date: 20200327 Year of fee payment: 6 Ref country code: SE Payment date: 20200326 Year of fee payment: 6 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20200327 Year of fee payment: 6 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20200326 Year of fee payment: 6 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200408 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200108 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200108 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200531 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200108 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20200326 Year of fee payment: 6 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200409 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200408 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200108 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200508 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200108 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602015045189 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200108 Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200108 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200108 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200108 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200108 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200108 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200108 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200108 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1221956 Country of ref document: AT Kind code of ref document: T Effective date: 20200108 |
|
26N | No opposition filed |
Effective date: 20201009 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20200331 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200319 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200319 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200108 Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200108 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200108 Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200108 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200331 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602015045189 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MM Effective date: 20210401 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20210319 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210401 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210331 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210331 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20211001 Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210320 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210319 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210331 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200108 Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200108 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200108 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200108 Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200108 |